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Summary of thesis    
 
 A large number of people require surgery, including total joint 
replacements, to treat bone and joint degenerative and inflammatory 
diseases.  Implant-related infections and failure of an implant to 
osseointegrate with the bone tissue are common causes of implant failure.  
Despite efforts to avoid initial bacterial adhesion on an implant surface, 
nosocomial infections do occur.  Hence, it is crucial to have the means to 
down-modulate the deleterious effects of bacterial endotoxins like 
lipopolysaccharide (LPS) on differentiating osteoblasts on the implant 
surface while treatment for the infection is given.  Implant failure is also 
partly attributed to the poor vascularization around the healing bone.  
Thus, in the present thesis, the aims are to develop an anti-bacterial, 
osteogenic substrate for bone cell differentiation, and to develop an 
angiogenic substrate to promote endothelial cell differentiation, as an 
adjunct to osteogenesis.  To address the concern of opportunistic bacterial 
infections at the bone-implant interface, a study is also done to evaluate 
the effects of a bioactive lysophospholipid on differentiating osteoblasts 
growing on the osteogenic substrate in the presence of a selected bacterial 
endotoxin.  Taken together, the work in the present thesis forms the basis 
for future work to be done in order to take the functionalized substrates 
closer to clinical applications.    
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General Introduction    
The initiative for the modification of bone implants    
 Bone and joint degenerative and inflammatory problems affect a large 
number of people worldwide.  It is believed that the number of afflicted people will 
continue to rise.  These diseases usually require surgical treatment, including 
total joint replacements in cases of severe degeneration of natural joints.  
Orthopaedic biomaterials are used in the fabrication of implantable medical 
devices to substitute, replace, or repair bones, cartilage or ligaments and 
tendons.  However, current bone implants have a limited lifespan.  An average 
implant lasts only about one to two decades.  Implant failure can result from the 
repeated cyclic mechanical stress of motion, which fragments the cement used to 
secure the implant to the bone.  Biomaterial debris around the bone-implant 
interface can cause osteolysis, a condition in which bone is gradually resorbed.  
Although osteolysis is a low-grade form of bone resorption, it eventually results in 
the loosening of an implant.  Revision surgery to replace the failed implant with a 
new one is a painful and costly procedure for the patient.  Besides the 
inconvenience of revision surgery, each replaced implant also has a shorter 
lifespan than the one which immediately precedes it.  Although non-cemented 
implant components have been used to get around the problem of cement 
failure, the success of this approach is not consistent.  This technique relies on 
the physical modification of the implant surface to render it porous, in an attempt 
to encourage bone growth into the porous surface.  Implant components are 
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fabricated from titanium, but bone often recedes from the cementless 
components as well. 
 Bacterial infection of a bone implant surface is another major cause of 
implant failure.  During surgical insertion of an orthopaedic implant, bacteria from 
the patient’s own skin and mucosa can enter the wound site.  Upon adhesion on 
the implant surface, the bacteria secrete a thick extracellular matrix and this 
leads to the formation of a bioflim.  The protective biofilm delays the action of 
antimicrobial agents, making the bacteria within the biofilm very resistant to host 
defence mechanisms and antibiotics [4].  Bacterial infection at an implant site can 
eventually result in localized bone destruction, leading to implant failure.  
Furthermore, the evolution of antibiotic-resistant bacteria limits the availability of 
effective antibiotics for the treatment of implant-related infections.   
 The failure of implant to osseointegrate with the host bone tissue and 
bacterial infection are the main reasons for much research into making implant 
surfaces that retard initial bacterial adhesion and promote bone formation at the 
tissue-implant interface.  The concept of using a cementless component bone 
implant, despite its present short-comings, is an attractive option to pursue in the 
quest for a longer-lasting prosthesis.  To this end, researchers have explored the 
idea of coating an implant surface with a bone-growth stimulating factor to 
encourage bone attachment onto the surface.  However, such biomimetic 
coatings have to be firmly attached to the implant surface to be resistant to any 
abrasions that the prosthesis may be subjected to during surgery.  The coating 
must also be resistant to the wear and tear of repeated cyclic mechanical stress, 
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and not delaminate at the implant metal interface.  Due to the highly corrosive 
environment of the human body, implantable devices consequently need to fulfill 
stringent requirements so that they do not corrode and release cytotoxic by-
products.  A biomaterial also must not induce an immunogenic response when it 
is implanted in a host.  Undesirable host response to an implant can result in 
implant failure due to host rejection of the prosthesis.  The process of bone 
regeneration is a unique one in the human body, in which angiogenesis plays a 
role.  A chapter in this thesis is dedicated to the surface functionalization of poly-
(lactic-co-glycolic acid) (PLGA) substrates with an angiogenic growth factor, to 
promote the differentiation of endothelial cells.  Thus, in this thesis the purpose of 
surface modification is to render the titanium substrates osteogenic and the 
PLGA substrates angiogenic, as an adjunct to osteogenesis. 
 
Introduction to biomaterials 
An overview of biomaterials in orthopaedics   
 The choice of biomaterials for use in an implant is a crucial process that 
involves rigorous tests to assess their mechanical and biochemical properties, 
and their biological interaction with tissues.  Hence, along the guidelines of 
mechanical properties and biocompatibility, the development of orthopaedic 
biomaterials conceptually evolved over three generations.  A review of the 
evolution of biomaterials over three generations will allow a better appreciation of 
the initiative and the subsequent aims of the work undertaken for this thesis.  The 
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wide range of orthopaedic biomaterials available necessitates the discussion to 
be focused on a few selected metals and biodegradable materials.   
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The first generation biomaterials    
 The first generation of orthopaedic biomaterials was mainly bioinert 
materials.  This generation of biomaterials was designed to match the physical 
properties of the replaced tissues, and would not elicit an immune response [5].  
Metallic materials of this generation that were successfully employed in 
orthopaedic applications were stainless steel and cobalt chrome-based alloys.  
Stainless steel implants were used in movable joints replacement parts but their 
poor wear resistance generated wear debris which resulted in osteolysis and 
local bone destruction, eventually leading to implant loosening.  Thus, stainless 
steel was replaced by the wear resistant cobalt chrome alloys for the fabrication 
of replacement parts that were subjected to constant cyclical stress.  Cobalt-
chrome-molybdenum (Co-Cr-Mo) alloys have exceptional corrosion resistance 
[6].  However, it is difficult to fabricate complex shapes using this alloy.  Another 
problem is the occurrence of large grain sizes despite the use of special casting 
techniques.  Notwithstanding these disadvantages, Co-Cr-Mo alloys possess 
properties superior to stainless steel.  Co-Cr-Mo alloys have higher intrinsic 
resistance to corrosion compared to stainless steel.  Metallic transfer which 
results in galvanic corrosion, which is thought to occur between surgical tool and 
implant is much less for Co-Cr-Mo implants than for stainless steel ones.  
Surface damage to the implant which inevitably occurs during the surgical 
insertion of the implant can lead to corrosive damage in stainless steel implants 
but does not seem to similarly damage Co-Cr-Mo ones.  However, the elastic 
modulus of these metals is higher than that of cortical bone.  Hence, when 
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placed in contact with cortical bone, these metals will take much of the load that 
originally acts on the bone, resulting in reduced loading on the bone.  This is 
known as the load sharing principle of the composite theory, and results in stress 
shielding.  Bone is a natural composite material comprising an organic phase, 
made up mainly of Type I collagen, and a mineral phase, made up of 
hydroxyapatite.  According to Wolff’s Law, bone that is subjected to stresses 
higher than baseline physiological levels responds with osteogenesis.  
Conversely, when subjected to stresses lower than physiological levels, bone 
atrophy occurs as the bone resorbs, eventually leading to implant failure.  
Although hydroxyapatite, which has the chemical formula, Ca10(PO4)6(OH)2, does 
not have the mechanical strength to be used for load bearing purposes, it is often 
used as a ceramic coating on metallic implant surfaces.  Being a bioactive 
material, a hydroxyapatite coating on the implant surface may serve to enhance 
osseointegration between implant and bone [7].     
 The use of titanium and its alloys in orthopaedics became popular after 
Branemark discovered the phenomenon of osseointegration [8].   Titanium and 
its alloys can tightly integrate into bone, greatly increasing the long-term 
behaviour of titanium-based implants and reducing the risks of implant failure.  
Titanium is a strong metal, and is very resistant to heat and corrosion.  However, 
it is very difficult to machine into desired shapes.  Its hardness, together with its 
high chemical reactivity with air, and other factors, has made titanium 
components very costly.  Nevertheless, titanium, due to its biocompatibility, in 
addition to its strength and excellent resistance to corrosion, is used in the 
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fabrication of components in implants and prosthetics.  There are several types 
of titanium alloys which have been developed for use.  The most commonly used 
titanium alloy is Ti-6Al-4V.  Another type of titanium alloy is Ti-4Al-4Mo-2Sn-
0.5Si, which is less commonly used.  Titanium and titanium alloys possess 
characteristics which make them a popular choice as a biomaterial for 
orthopaedic applications.  Their hardness confers strength which allows them to 
be used for load-bearing applications.  They also possess bend strength and 
fatigue resistance, which are important in load-bearing structures that are 
constantly subjected to the cyclic stress of motion.  Ti-6Al-4V has a lower density 
than other metals that are used as biomaterials, making it comparably lighter.  As 
an example, Ti-6Al-4V has a density of 4.40 g cm-3 while cobalt-chrome alloy has 
a density of approximately 8.5 g cm-3.  In terms of their elastic modulus, Ti-6Al-4V 
has a magnitude of 106 GPa while that of cobalt-chrome alloy is 230 GPa.  
Elastic modulus is a measure of a substance’s tendency to be deformed non-
permanently, that is, elastically.  A substance with a low elastic modulus is 
flexible.  A rigid biomaterial may cause bone atropy due to stess shielding and 
interference with blood circulation, which causes the bone to weaken.  Hence, Ti-
6Al-4V would be a more suitable choice than cobalt-chrome alloys for use in 
regions of the body which experience bending stresses.  From a biomechanical 
perspective, Ti-6Al-4V would thus be less likely to cause bone atrophy and 
resorption.  Although titanium has excellent corrosion resistance, its wear 
properties are poor.  There are concerns that wear debris from titanium-based 
joint replacement implants could be cytotoxic or cause tissue reactions [9, 10].   
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A common feature of first generation biomaterials is the adsorption of 
unspecific proteins on the surface of the materials.  A diverse array of unspecific 
proteins thus elicits the unspecific signaling to the cellular environment.  
Ultimately, a fibrous layer forms and encapsulates the implant.  Thus, in the 
second generation of biomaterials, the aim is to develop bioactive interfaces 
which elicit a specific biological response.   
 
The second generation biomaterials   
 The second generation of biomaterials is characterized as bioactive 
materials which interact with the biological environment to induce specific 
responses, as well as resorbable materials which support tissue development 
while progressively degrading into harmless products.  The development of 
bioactive surfaces which promote mineralization and bonding between bone and 
implant is a common functionalization process to enhance osseointegration.   
 Although no metallic surface is bioactive per se, metals can be rendered 
bioactive by anchoring bioactive molecules onto their surface (surface 
functionalization).  Metals can be functionalized using methods of physical or 
chemical modification of the surface.  Physical surface modification includes 
electrophoretic deposition, plasma spraying and laser ablation [11-13].  Various 
chemical methods have also been developed to activate a material surface.  
Kokubo et. al.  developed a thermochemical treatment which results in the 
formation of a thin titanate layer on a material surface that is able to form a dense 
bone-like apatite layer when immersed in a physiological medium [14].  Various 
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other chemical treatment methods including etching with hydrogen peroxide have 
also been developed [15, 16].    
 Resorbable polymers are the focus of the second generation of polymers.  
These biodegradable polymers undergo a controlled chemical breakdown and 
the polymer chains are resorbed.  Examples of biodegradable polymers are 
polyglycolide (PGA), polylactide (PLA), poly(ε-carprolactone) (PCL), chitosan and 
hyaluronic acid.  Kulkarni et. al. introduced the concept of biodegradable 
polymers, and these materials have been used in many orthopaedic applications 
such as repair of bone fractures and bone substitution [17, 18].  These polymers 
are also used for making sutures, screws and pins [19].  The use of 
biodegradable polymers in orthopaedic application has several advantages over 
metallic ones.  As the polymers gradually degrade, they help to reduce the 
problem of stress shielding that are typical of metallic implants.  Biodegradable 
polymers also eliminate the need for subsequent surgeries that may sometimes 
be necessary to remove metallic implants.  Finally, biodegradable polymers 
enable post-operative diagnostic imaging without artefacts, unlike metals.   
 Due to the hydrolytic sensitivity of biodegradable polymers, moisture must 
be avoided during thermal processing of the polymers [20].  The biodegradation 
of these polymers is mainly initiated by hydrolysis, although enzymatic activity 
may to a lesser extent, play a role [21, 22].  Various factors control the 
degradation times of the polymers.  The molecular weight of the polymer, 
polymer crystallinity, monomer concentration, porosity, geometry and location of 
the implant are factors that determine how quickly a polymer will degrade.  In 
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what is termed ‘bulk degradation’, when an implant is in an aqueous 
environment, water will enter the bulk of the polymer and preferentially attack the 
chemical bonds of the amorphous phase, thereby shortening the polymer chain, 
following which water attacks the chemical bonds in the crystalline regions of the 
polymer [23].  In the second stage of degradation the acidic breakdown products 
autocatalyse the degradation process.  The resulting lower crystallinity and size 
of the implanted device, and the presence of a larger amount of reactive 
hydrolytic groups in the polymer backbone eventually contribute to hastening the 
degradation process [24, 25].  A relevant example of this form of degradation is 
poly (lactic-co-glycolic acid) (PLGA).  The breakdown products are lactic acid and 
glycolic acid which are enzymatically converted and fed into the tricarboxylic acid 
(TCA) cycle in the mitochondria.  The final products are ATP, water and carbon 
dioxide.  Water and carbon dioxide are then excreted by the lungs and kidneys 
[26, 27].  Another consideration of the use of a degradable polymer like PLGA for 
orthopaedic applications is mechanical strength, which can be improved by self-
reinforcing the material with oriented fibres or fibrils of the same material.  Some 
natural polymers like chitosan and collagen have intrinsic bioactive activity in 
some tissues, for example, cartilage tissue.  The bioactivity of polymers depends 
on the functional groups and binding sites available on the polymer surface.  
Hence, the bioactivity of polymers can be modified by coupling certain polymers 
or biomolecules onto their surface.  Metals and ceramic surfaces can be similarly 
modified in this way.  For second generation biomaterials, the modification of 
polymer surfaces is achieved by physical adsorption of proteins and peptides 
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onto the surface, by dip-coating, or by amino- and carboxyl-directed 
immobilization of biomolecules [16].  The surfaces of polymers can also be 
chemically modified to induce their mineralization with HA layers [15].   
 
The third generation biomaterials   
 The third generation biomaterials are materials engineered to be able to 
stimulate specific cellular responses at the molecular level [18, 28].  Third 
generation biomaterials debuted at about the same time as scaffolds were 
developed for tissue engineering applications.  Temporary three-dimensional 
porous scaffolds that are able to promote cell adhesion, proliferation and 
differentiation are being developed [26, 29, 30].  Biomaterial surfaces 
functionalized with peptide sequences to mimic the extra-cellular matrix (ECM) 
are being developed as well.  Due to the limitations of tissue transplantation and 
grafting such as rejection, costs, disease transfer, donor scarcity and post-
operative morbidity, tissue engineering is seen as an attractive alternative 
solution [28, 31, 32].  There is current active research in tissue engineering and 
regenerative medicine to repair organs and tissues, using stem cells, growth 
factors and peptide sequences, in conjunction with synthetic scaffolds [33].  
Other issues like angiogenesis and nutrient delivery which are crucial to tissue 
regeneration also need to be addressed.  Despite the promising therapeutic 
potentials that tissue engineering offers, there are many concerns that still need 
to be addressed.  Tissue engineering necessitates the manipulation of cells, 
which requires technical competence.  Cell manipulation could also raise ethical 
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concerns.  Very often, tissue engineering is a multi- and inter-disciplinary field, 
and work must be well-coordinated among workers in the relevant fields like 
biology, chemistry, physics, engineering and medicine.  Clinically, new surgical 
procedures may need to be developed to complement the advancements in the 
tissue engineering field.   
 
Modified biomaterials 
 The outcome of the interaction between biological systems and materials 
is dependent in large part upon the surface properties of the materials.  Important 
properties to be considered include the physico-chemical nature, the topography, 
the mechanical properties, and the bio-functionality of the material surface.  The 
surface properties of a material interact with biological entities like water, 
biological molecules, cells, and tissues, which come into contact with it. Many 
techniques are available to modify a material surface for the desired effect.  
Some examples of the current techniques include gas plasma treatments, ion 
bombardment, chemical and physical vapour deposition, coating of ceramics, 
metals and polymers, as well as coating of material surfaces with peptides, lipids 
and sugars. 
 In the subsequent chapters, details of the techniques used to functionalize 
selected titanium substrates and to coat the poly (lactic-co-glycolic acid) (PLGA) 




Choice of biomaterials for osteoblast differentiation  
Titanium  
 Titanium alloys are widely used in the fabrication of orthopaedic implants, 
owing to their strength-to-weight ratio and biological inertness.  Besides being 
biocompatible, titanium alloys are also able to osseointegrate.  Bone cells have 
been known to attach onto the surface of titanium-based hip and joint 
replacement implants.  Although inherently osteogenic, bone cell attachment 
onto untreated titanium alloy surface is often insufficient for full osseointegration 
to occur.  Hence, improvements in the techniques of surface modification of 
titanium alloys are continually being made to enhance bone cell adhesion and 
proliferation properties.  Other modifications include the grafting of osteogenic 
factors onto the metal surface to further promote osteogenesis on the implant 
surface.  Besides enhancing bone formation on the implant surface, biomimetic 



























 Chitosan is a linear polysaccharide comprising randomly distributed β–(1-
4)-linked D-glucosamine, which is the deacetylated unit, and N-acetyl--
glucosamine, the acetylated unit.  It has the potential to be used in biomedical 
applications.  Chitosan is derived from chitin, the structural element in the 
exoskeleton of crustaceans, and is commercially produced by the deacetylation 


















of chitin.  The degree of deacetylation of commercially produced chitosan ranges 
between 60% and 100%. 
 The amino group of chitosan has a pKa value of approximately 6.5.  Thus, 
chitosan is positively charged, and is soluble in acidic to neutral solution, 
depending on the pH of the solution and the degree of deacetylation of the 
chitosan used.  The positive charge makes chitosan bioadhesive, binding to 
negatively charged surfaces like mucosal membranes.  Chitosan is a 
biocompatible and biodegradable substance.  Its biocompatibility and its 
bioadhesive property make chitosan a potentially useful coating material for the 
functionalization of other biomaterials.  Studies have shown that chitosan 
possesses osteoinductive potential [34-37].  Composite scaffolds containing 
chitosan have also been shown to support for the attachment and proliferation of 
osteoblast cells [24, 38-40].  In another approach, chitosan was chemically linked 
onto a polylactic acid membrane surface using carbodiimide chemistry.  This 
membrane was shown to support the growth of osteoblasts [33, 41].  Another 
very important attribute of chitosan is its anti-bacterial property [36, 42].  A 
composite film of keratin-chitosan showed resistance against bacteria while 








































































 Dextran is a complex, branched polysaccharide comprising glucose 
chains of varying lengths.  Dextran immobilized onto material surfaces has been 
found to limit cell adhesion and spreading [43].  Thus dextran has been 
suggested for use as an effective low protein-binding, cell-resistant coating on 
biomaterial surfaces [44].  Hence, it is reasonable to speculate that dextran 
would similarly resist bacterial cell adhesion.  However, the disadvantage of 
using dextran for surface coating biomaterials is due to the highly toxic and 
expensive sulfonyl chloride reagents used [45, 46].  The reactions also need to 
be carried out under stringent anhydrous conditions.  These difficulties have 
been largely overcome with the availability of a method described that requires 
less toxic reagents and less stringent reaction conditions [43].   
 Immobilized dextran possesses the potential for multivalent, high density 
immobilization of bioactive molecules [44, 47].  This distinct advantage of dextran 
makes it an attractive polymer to be used as a biointeractive coating on bone 
implant surfaces.  Dextran has also been shown to be a biocompatible molecule 
and therefore should not induce an adverse response if used in vivo.  Dextran 
mimics the glycocalyx on cell surfaces and has been shown to be well-tolerated 
in animal studies [43].  Furthermore, dextranase, the enzyme that degrades 
dextran, is produced by bacteria and not by tissues [48].  Hence, other than 
tissues that have significant microbial populations, dextran implants and dextran-
coated material surfaces will not degrade enzymatically in most tissues [48].  
Recent studies have further shown that surface-immobilized dextran on 
biomaterials are resistant to dextranase-mediated degradation and thus should 
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be stable in most tissue environments [49].  Thus, dextran coated surfaces 
prevent non-specific protein and cell attachment, and can be grafted with cell 
adhesion ligands to promote the attachment of specific cell types, to develop 
well-defined surface modifications that promote specific cell interactions [44].  
This could potentially result in well-defined surface modifications to bring about 





Choice of biomaterials for angiogenesis 
Poly (lactic-co-glycolic acid) (PLGA) 
 PLGA has been widely used to fabricate drug delivery matrices in the 
forms of microspheres, microparticles, nanoparticles, tablets, wafers and 
scaffolds [50-60].  The potential uses of PLGA include tissue engineering 
applications, medical therapy and drug delivery.  PLGA biomaterials degrade in 
vivo by hydrolysis into lactic acid and glycolic acid.  These two breakdown 
products are fed into the tricarboxylic acid cycle and excreted [61].  PLGA 
degradation occurs in four steps.  Initially, water penetrates the amorphous 
region of the polymer and disrupts the secondary forces.  This is followed by the 
cleavage of the covalent bonds in the polymer backbone by hydrolysis.  As 
hydrolysis proceeds, the carboxylic end groups of the polymer autocatalyse the 
hydrolysis reaction.  As massive cleavage of the covalent bonds in the polymer 
backbone ensues, there is significant mass loss.  Finally, erosion occurs as 
monomers and oligomers leave the polymer bulk, resulting in the loss of weight 
[23].  Chemical degradation by hydrolysis is an important degradation 
mechanism in PLGA structures.  However, PLGA structures contain hydrolysable 
ester bonds.  Hence enzyme-catalyzed hydrolysis also contributes to the 
chemical degradation process of PLGA [62].  Enzyme-catalyzed hydrolysis is an 
important consideration in the design of PLGA-based biomaterial implants and 
devices with PLGA coatings for in vivo applications.  Serum albumin, an 
important protein of blood plasma, has an esterase-like activity.  While serum 
albumin may not alter the degradation mechanism, it increases the initial velocity 
 35 
of the hydrolytic de-esterification process of glycolic acid-containing copolymers 
like PLGA [63].  Thus, when PLGA comes into contact with blood in vivo, its 
degradation rate may be significantly altered, which in turn will affect the release 
kinetics of a drug or bioactive molecules that are attached onto the PLGA matrix.   
 Besides water permeability and enzyme-mediated hydrolysis, the 
degradation of PLGA depends on a multitude of other factors [64, 65].  
Temperature, pH, monomer ratio of the constituent lactic acid and glycolic acid, 
site of implantation, attachment of bioactive molecules and inflammation are 
some other factors that may affect the degradation kinectics of PLGA, and 
consequently alter the release kinectics of any bioactive molecule loaded onto 
the PLGA surface [65].  In previous studies elevated temperatures have been 
used to accelerate PLGA degradation and drug release from PLGA devices. [65].  
Besides the effect of temperature, the thickness of the PLGA material also 
affects its degradation rate [66].  The degradation rate of PLGA in vitro is likely to 
differ from that in vivo.  This is because the degradation process of PLGA is 
autocatalytic [67, 68].  The accumulation of acidic degradation products of PLGA 
causes a decrease in pH, and autocatalyzes the degradation process in vitro.  
However, this accumulation of acidic breakdown products is unlikely to occur in 
vivo.  In vivo environments are dynamic, where body fluids and circulating blood 
would carry away the breakdown products constantly, preventing the build-up of 
acidity around the PLGA implant.  Thus, a PLGA material would degrade 
comparatively more rapidly in vitro compared to that in vivo, which demonstrates 
that environmental conditions affect the degradation rate of PLGA [68].  A study 
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has shown that PLGA degradation rates in vitro are greater if no media change 
was done, which removes the acidic breakdown products, than if media was 
changed periodically [63].  Furthermore, the polymer composition of the 
monomeric units of PLGA also contributes to the differences in degradation rates 
[68].  
Thus, the degradation of PLGA is dependent upon a number of factors 
operating simultaneously.  In vitro studies conducted on PLGA degradation may 
yield results that do not actually reflect the in vivo situation.  Unlike static 
conditions in vitro, the in vivo environment, by virtue of its dynamic nature, 
constantly changes and the PLGA degradation rate is thus correspondingly 
altered.  Nevertheless, in vitro studies using a series of combinations of variables 
to simulate specific in vivo situations can yield a reasonable amount of useful 
information for the fabrication of PLGA-based biomaterials, like controlled release 
devices.   
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Introduction to the biological aspects of implants 
Mesenchymal stem cells (MSCs)   
MSCs are a population of multipotent, heterogeneous mesenchymal 
stromal cells [69].  These cells can proliferate in vitro as plastic-adherent cells.  
MSCs have a fibroflast-like morphology, can form colonies and can differentiate 
into bone, cartilage and fat cells.  Although MSCs have been isolated from 
almost every type of connective tissue, the characterization of these cells is 
based mainly on bone marrow-derived MSCs [70].  The general consensus is 
that human MSCs lack the haematopoietic markers CD45, CD34 and CD14, as 
well as the co-stimulatory molecules CD80, CD86 and CD40.  MSCs express 
variable levels of CD105, otherwise known as endoglin, CD 44, which is a cell 
surface glycoprotein that acts as a receptor for hyaluronic acid and other ligands 
like collagen, osteopontin and matrix metalloproteinases, and CD271, which is 
the low affinity nerve growth receptor, alternatively known as the LNGFR or p75 
neurotrophin receptor.  Besides the ability to differentiate into osteoblasts, MSCs 
have also been shown to differentiate into pericytes and endothelial cells, 
implicating their potential role in supporting haematopoieis [71].  The migratory 
capability of MSCs is a useful feature that has been demonstrated in in vivo 
studies [72].  Hence, the homing ability of MSCs is an attractive feature to exploit 
for potential therapeutic purposes in orthopaedic applications.   
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Bone morphogenetic proteins (BMP)    
 Bone morphogenetic proteins are cytokines belonging to the transforming 
growth factor beta (TGF-β) family, and more than 20 BMPs have been identified 
to date [73].  BMPs are synthesized as prepropeptides comprising 400 – 500 
amino acids consisting of a signal domain, a predomain and a mature domain.  
BMPs dimerize by forming disulphide bridges.  Upon cleavage of a Arg-X-X-Arg 
sequence in the C terminal domain, BMPs become active cytokines.  
Demineralized bone contains BMPs which have been found to stimulate ectopic 
bone formation in vivo [33].  Some BMPs like BMP2 can also be produced by 
preosteoblasts [73].  Besides their roles in the development of the skeleton and 
the maintenance of homeostasis during bone remodeling, BMP2 is also 
implicated in other biological processes like embryogenesis and angiogenesis 
[74].  Thus, BMPs have potential biomedical role as therapeutic agents.   
 BMPs prevent mesenchymal progenitor cell differentiation into myoblasts, 
and the transcription factor, Runx2, appears to play an important role in this 
process, by inducing matrix gene products and inhibiting myotube formation [1].  
Runx2 expression seems to be low in mesenchymal progenitor cells.  BMPs act 
on these progenitor cells to induce the upregulate Runx2 expression.  However, 
Runx2 alone is insufficient in inducing osteoblastic differentiation.  Runx2 
subsequently needs to interact with BMP-specifc transcription factors called 
receptor-regulated Smads (R-Smads) to induce the mesenchymal progenitor 
cells into osteoblastic cells.  In summary, the synergistic action of BMPs with 
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Runx2 and R-Smads is essential in inducing osteoblastic cell differentiation from 

















































































Induces osteoblast differentiation 
Runx2  
Dlx5  
Osteoprogenitor cells Osteoblasts  
Fig. 1.3.  Induction of osteoblast differentiation by BMPs through Runx proteins.  
Upon ligand binding onto the types I and II serine/threonine kinase receptors (R-I, R-II), 
the R-II receptor transphosphorylates the R-I receptor.  The activated R-I receptor then 
phosphorylates the R-Smad, which in turn complexes with common-partner Smads (Co-
Smads) to form the Smad complex.  The Smad complex translocates into the nucleus.  In 
the nucleus, the Smad complex binds directly to specific DNA sequences as well as 
interact with various transcription factors and transcriptional coactivators/corepressors, 
leading to the transcriptional regulation of target genes.  BMPs induce the expression of 
Runx2 through Dlx5 in the osteoprogenitor cells and inhibits myoblast differentiation.  
BMP-specific R-Smads then interact with Runx2 and other proteins to induce osteoblast 
differentiation. (Adapted from Miyazono et. al.  Oncogene 23 (2004). pp. 4232-4237.) 
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 Vascular endothelial growth factor (VEGF) 
 Bone healing is a multistep regenerative process which involves 
coordinating angiogenesis with bone homeostasis [75].  Angiogenesis plays a 
central role in the bone regeneration process [76].  Angiogenesis is regulated by 
two main hormonal pathways, namely, the VEGF pathway and the angiopoietin 
pathway [77].  However, the VEGF pathway is the more important of the two 
pathways.  Originally described as the tumour vascular permeability factor, VEGF 
was finally discovered and characterized in 1989 [78, 79].  Human VEGF exists 
as isomers, the most important VEGF isomers being VEGF121, VEGF165, 
VEGF189 and VEGF206.  Angiogenesis has an especially important role in 
endochondral ossification [80].  During this process, avascular cartilagenous 
tissue is gradually transformed into vascular osseous tissue.  VEGF is expressed 
by the hypertrophic chondrocytes in the epiphyseal growth plate.  VEGF 
promotes vascularization of the cartilage by metaphyseal vessels.  This results in 
new bone formation.  Blocking VEGF binding to the VEGF receptors resulted in 
the suppression of vascularization of the cartilage and bone formation, which are 
restored upon termination of anti-VEGF treatment [81].  Thus, VEGF mediates 
the essential condition of vascularization that is required for the complex 
endochondral ossification.  There is also evidence of the role of VEGF in 
intramembraneous ossification [75]. 
The mechanism of action of VEGF in endothelial cells begins with the 
binding of VEGF to the VEGF receptor.  Following which, a cascade of 
intracellular signaling events begins with the dimerization and 
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autophosphorylation of the intracellular receptor tyrosine kinases [2].  This results 
in the activation of several downstream protein pathways, leading to some of the 
key biologic effects on endothelial cells (Fig. 1.3).  The protein kinase c (PKC)-
mediated activation of the protein kinase Akt, otherwise known as protein kinase 
B (PKB), mediates VEGF-dependent endothelial cell signaling and function [82].  
This PKC-dependent Akt activation by VEGF was demonstrated through the use 
of several PKC inhibitors, which prevented the VEGF-stimulated Akt activation 
[82].  Endothelial cell migration has been shown to be regulated by the p38 
mitogen-activated protein kinase (p38MAPK) pathway [83].  P38MAPK regulates 
the expression of urokinase plasminogen activator (uPA), which mediates the 
migration of several cell types including endothelial cells.  uPA involvement in 
endothelial cell migration has been demonstrated by the use of agents that 
disrupt the uPA-uPA receptor interaction, which abrogated the cell migration 
process.  Thus, VEGF-mediated endothelial cell migration is regulated through 
uPA, whose expression is in turn regulated by p38MAPK.  The process of 
endothelial cell proliferation has been investigated in a study which found that the 
transcription factor serum response factor (SRF) is critical for endothelial cell 
proliferation and angiogenesis [84].  Also through the use of specific inhibitors, it 
was found that the activation of SRF requires the MEK/ERK and Rho signaling 
[ERK – extracellular signal regulated kinase; MEK – the immediate upstream 
activator kinase of ERK, otherwise known as MAP kinase (MAPK) or ERK 
kinase; Rho is a member of the family of small GTPases, which are G-proteins 
found in the cytosol].  Treatment of endothelial cells with each type of specific 
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inhibitor abrogated the VEGF-induced SRF expression.  Furthermore, in vivo 
experiments using SRF antisense RNA to knock down SRF protein levels 
demonstrated that SRF deficiency inhibits angiogenesis.  Taken together, SRF is 
a critical requirement for VEGF-induced angiogenesis and endothelial cell 
migration and proliferation.  VEGF induces the SRF protein expression, its 
nuclear translocation and DNA binding activity in endothelial cells, a process that 

































Fig. 1.4.  VEGF receptor binding and intracellular signaling. (Adapted from 
























 Much work has been done on VEGF in recent years [85].  However, the 
role of VEGF in bone formation and angiogenesis is still not fully understood.  
VEGF has potential clinical applications as an adjunct to the osseointegration of 
bone and implant in areas of poor vascular supply.  Hence, the use of VEGF to 
functionalize biomaterials for clinical applications remains to be explored.  In this 
work, the release of VEGF from a PLGA substrate and the ability of the released 
VEGF to mediate endothelial cell differentiation from hMSCs are studied.   
 
Introduction to the relevant aspects of osteoimmunology 
 In order to better appreciate the significance of the work done in chapter 6, 
the relevant aspects of osteoimmunology in the chapter wherein the LPS-
CD14/TLR4/MD2 interaction, TNFα and S1P are discussed below.   
(LPS – Lipopolysaccharide, TLR4 – Toll-like receptor-4, tumour necrosis factor-α (TNFα) and 
sphingosine-1-phosphate (S1P))    
 
The LPS-CD14/TLR4/MD2 interaction 
 LPS is a major component of the outer cell membrane of Gram-negative 
bacteria, acts as an endotoxin and is able to elicit strong immune responses in 
the body.  Dendritic cells stimulated with LPS showed an increase in the 
expression of TNFα mRNA and protein levels [86].  LPS comprises three 
structural components: a core oligosaccharide, an O-specific chain made up of 
repeating sequences of polysaccharides and a lipid A component, which is 
responsible for the proinflammatory properties of LPS [87].  LPS has been 
reported to activate Toll-like receptor-4 (TLR4/CD284) [88].  Toll-like receptors 
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(TLR) are a family of mammalian proteins.  Mammalian Toll-like receptors are 
Microbe Associated Molecular Pattern (MAMP) receptors and thus recognise 
bacterial common structures [89].  TLR4 is an LPS ligand and has been found to 
be essential for LPS responsiveness in vivo [90].  TLR4 is part of a receptor 
complex comprising two other molecules, CD14 and MD2.  Like the other 
mammalian Toll-like receptors, TLR4 is a MAMP receptor which recognizes LPS 
and thus functions as a LPS ligand [89, 91, 92].  CD14 is also a pattern 
recognition receptor and LPS is its main ligand.  CD14 thus functions as a co-
receptor of the CD14/TLR4/MD2 receptor complex.  The MD2 protein is encoded 
by the human gene, Lymphocyte antigen 96.  MD2 associates with the TLR4 to 
confer responsiveness to LPS, thereby mediating the extracellular to intracellular 
LPS signalling [93].  Fig. 6.7 is a schematic to illustrate the association of LPS 















Fig. 1.5.  This schematic illustrates the association of LPS with the 
CD14/TLR4/MD2 receptor complex on the cell surface.  CD14 and TLR4 are 
pattern recognition receptors which recognise LPS.  MD2 is a protein which 
interacts with TLR4 to mediate the extracellular to intracellular LPS signaling.   
LBP (lipopolysaccharide binding protein) is an integral membrane protein which 
is involved in the acute-phase immunologic response to Gram-negative bacterial 






















TNFα       
 TNFα is a member of a large family of inflammatory cytokines that share 
common signal pathways [94].  Like the other inflammatory cytokines, it activates 
the transcription factor NFκB and stimulates the apoptotic pathway.  In bone, 
TNFα plays a central role in bone pathophysiology, and attacks bone at many 
levels  [94].  It stimulates osteoclastogenesis and simultaneously inhibits OB 
function.  TNFα inhibits the recruitment of osteoprogenitors from the bone 
marrow, suppresses the expression of matrix protein genes while upregulating 
the expression of genes that mediates osteoclastogenesis, and inducing OB 
resistance to 1,25-dihydroxyvitamin D.  Bone-related genes like Runx2 and OCN 
have also been reported to be downregulated by TNFα [95, 96].  At the same 













S1P    
 S1P is a bioactive lysophospholipid that acts both intracellularly and 
extracellularly [98].  It induces a wide spectrum of biological responses like cell 
survival, growth and migration [99-103].  S1P has been shown to be a potent OB 
mitogen [104].  It has been proposed that S1P functions to regulate the migration 
of osteoprogenitors from the bone marrow to the bone formation site, through its 
receptor, S1P2 [105].  Thus, S1P helps to preserve the osteoprogenitor pool in 
marrow by ensuring that only mature osteoprogenitors are mobilized.  It also 
regulates osteoclastogenesis by increasing RANKL in OBs [98].   
Besides its roles in bone cell related functions, S1P appears to also 
mediate important roles in vascular biology.  Experiments were conducted using 
transgenic mice that overproduce endogenous S1P, as well as mice with 
ischaemic limbs given intramuscular administration of S1P.  The results showed 
that S1P promotes post-ischaemic angiogenesis and blood flow recovery [106].  
It has also been proposed to embed S1P in polymeric thin films to be gradually 
released for therapeutic arteriogenesis [107].  
S1P has also been indicated to be able to protect against damage caused 
by endotoxin-induced inflammation [108].  One of the receptors for S1P is S1P1, 
which has been shown to act in unison with TLR4 to regulate IFNβ in human 
primary gingival epithelial cells [109].  IFNβ exerts an anti-inflammatory effect by 
inhibiting TNFα production [110].  Interestingly, S1P has also been shown to 
induce an anti-inflammatory phenotype in macrophages through the S1P1 
receptor on the macrophages [111].  S1P is also able to cross-activate the TGFβ 
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signaling pathway in renal mesangial cells and mimic TGFβ induced cell 


















Conclusion    
 Although biomaterials are continually being improved upon, currently, 
biomaterials from all three generations still have a relevant role to play.  
Developments in materials science must match the biological complexity at the 
molecular level, so that biomaterial surfaces can be tailored for different specific 
purposes of implant integration and tissue regeneration.  Such tasks would need 
the synergistic, coordinated efforts of the various scientific, engineering and 
medical disciplines.  The purpose of functionalizing an implant surface by the 
physical or chemical modification of its surface is to render it capable of 
supporting various cellular functions.   Beside the engineering perspective of 
biomaterials, the biological aspect of tissue engineering also plays a critical role 
in regenerative medicine.  Thus, the choice of the appropriate cell type for use 
with functionalized biomaterials will synergize with the body’s physiology to 
enhance the integration of an implant with host tissues.  Due to wide range of 
orthopaedic biomaterials available, the scope of work and discussion in this 
thesis will focus on Ti-6Al-4V, a metallic biomaterial, with a chapter dedicated to 
the studies using PLGA, a bioresorbable polymer.  Within this scope, discussions 
on the work done will include the surface modification of Ti-6Al-4V to render it 
anti-bacterial and osteogenic.  An osteoconductive titanium surface may have a 
better potential to osseointegrate with host bone tissue and thus reduce the 
chances of implant loosening.  Following the initial work to render the titanium 
surface osteogenic and resistant to bacteria, further work is done to improve on 
the technique of attaching BMP2 onto the titanium surface.  This improved 
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substrate is then used to simulate the effects of bacterial infection on 
differentiating osteoblasts, and to study the ability of a selected bioactive 
molecule in countering the deleterious effects of the bacterial endotoxin, LPS. 
The discussion will also include the use of PLGA for the fabrication of a 
controlled release angiogenic substrate.  The process of angiogenesis is 
important to the proper healing of bone repair and wound healing.  Together, an 
implant with an osteoconductive surface and a biomimetic material that supports 
angiogenesis, coupled with cells that possess multi-lineage differentiation 







General materials and methods    
 Materials and methods common to chapters 3, 4, 5, 6 and 7 are described 
below.  Materials and methods specific to each of the chapters mentioned above 
are described in the corresponding chapters (denoted by # against the 
appropriate sub-headings below). 
 
Materials     
Ti-6Al-4V (subsequently denoted as Ti) foils were purchased from 
Goodfellow of Cambridge (UK).  Chitosan (CS) was purchased from CarboMer 
(San Diego, US) and refined twice by dissolving it in dilute acetic acid solution, 
filtered, then precipitated with aqueous sodium hydroxide and dried in a vacuum 
oven for 24 h at 40oC. The viscosity-average molecular weight was 
approximately 2.2 X 105 as determined by the viscometric method. The degree of 
deacetylation was 84% as determined by elemental analysis using the Perkin-
Elmer Model 2400 elemental analyzer [113].  3,4-dihydroxyphenylalanine 
(dopamine), glutaraldehyde, dextran (MW = 70 000), sodium periodate, sodium 
borohydride, dexamethasone, β-glycerophosphate and ascorbic acid were 
purchased from Sigma-Aldrich Chemical Co. (Singapore).   Ultrapure water 
(>18.2 MΩ cm, Millipore Milli-Q system, Singapore) was used in the experiments.  
All materials used in cell culture were purchased from Gibco, Invitrogen 
(Singapore). Flow cytometry was done using the CyAnTM ADP Analyzer.  
Fluoroisothiocynate (FITC)-conjugated CD44 and phycoerythrin (PE)-conjugated 
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CD105 antibodies were purchased from eBioscience (San Diego, US), CD271-
FITC was purchased from Miltenyi Biotec (GmbH, Germany), and CD34-FITC 
and CD45-FITC were purchased from AbD Serotec (UK).  BMP2 was purchased 
from USBiological (US).  The intensity and stability of BMP2 attached onto the 
chitosan-grafted titanium substrate surface were assessed using the Bio-Rad DC 
Protein Assay (US).  RNA and protein concentrations were measured using the 
NanoDrop ND1000 spectrophotometer.  RT-PCR was done using the BIORAD 
iCycler.  The CellQuanti-MTTTM cell viability assay kit and the QuantiChromTM 
alkaline phosphatase (ALP) assay kit were purchased from BioAssay Systems 
(US).  Human mesenchymal stem cells (hMSC) were purchased from Lonza 
(Lonza Walkersville Inc., USA.  Product number: PT-2501).  Human osteoblasts 
(hFOB) were purchased from the American Type Culture Collection (ATCC, 
USA.  Product number: CRL-11372). 
 
Preparation of surface modified titanium substrates # 
 The preparation of each specific type of surface modified titanium 




Characterization of the titanium substrates   
The characterization of the Ti-CS and Ti-Dex substrates was done by the 
staff of Department of Chemical and Biomolecular Engineering, Faculty of 
Engineering, National University of Singapore [114, 115].  The chemical 
composition of the surfaces was analyzed by X-ray photoelectron spectroscopy 
(XPS) on an AXIS HSi spectrometer (Kratos Analytical Ltd., UK) with an AlKα X-
ray source (1486.6 eV photons). The details for the XPS measurements are 
similar to those reported earlier [116].  All binding energies (BEs) were 
referenced to the C 1s hydrocarbon peak at 284.6 eV. In the peak synthesis, the 
line width (full width at half-maximum) of the Gaussian peaks was kept constant 
for all components in a particular spectrum.   
 
Stability and surface density of BMP2 on the surface modified titanium  
substrates 
 To assess the stability of BMP2 on the surface modified titanium 
substrates, the substrates were placed individually in a 24-well plate containing 1 
ml of PBS per well.  The intensity of the BMP2 on the substrate surface was 
assessed on days 0, 1, 3, 5 and 7.  At each respective point in time, the 
substrates were removed and placed in a new well each.  1 ml of PBS was then 
added to each well, and the attached BMP2 was scrapped off the substrate 
surface with 20 strokes of a cell scraper.  An alternative method of detaching the 
bound BMP2 is to immerse the substrates individually in a 1N HCl solution at 
50oC for 24 hours [117].  The solution is then neutralized with 0.1 NaOH to pH 
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7.0 before the concentration of BMP2 is determined.  However, the use of HCl 
could possibly result in some degree of denaturation of the BMP2 [117].  In the 
case of the Ti-Dex-BMP2 substrate, the interference by the dextran chains could 
also result in inaccurate determination of the amount of BMP2 [117].  Hence, the 
method of detaching the bound BMP2 from the substrate surface by scrapping is 
chosen for this study.  The amount of BMP2 in solution was then measured using 
the Bio-Rad DC Protein Assay, following the manufacturer’s instructions. The 
colour intensity of the reaction mixture was measured at 700 nm using an 
absorbance plate reader after an incubation period of 15 min.  The amount of 
attached BMP2 on day 0 is the initial coating density, while those on days 1, 3, 5 
and 7 give an indication of the stability of BMP2 on the substrate surface.  The 
absolute amount of BMP2 adsorbed onto the substrate surface, that is, the initial 
coating density, was measured as described above, using a series of BMP2 
solutions of known concentrations as standards.    
 
Culture of bone marrow-derived stromal cells (BMMSC)    
 Bone marrow was taken with written consent from patients undergoing 
surgery for rheumatoid arthritis.  The marrow was washed 3 times with copious 
Hanks Balanced Salt Solution (HBSS).  Erythrocytes were lysed with a 0.8% 
ammonium chloride solution and the bone marrow cells were centrifuged at 300 
g for 10 min.  The cell pellet was then washed 3 times with HBSS, resuspended 
and cultured in a medium comprising Minimal Essential Medium-alpha (MEM-α), 
supplemented with 10% foetal bovine serum (FBS), L-glutamine (2mmol/l), 
 57 
penicillin (100 U/ml) and streptomycin sulphate (100  µg/ml), and incubated at 
37oC in a humidified atmosphere of 5% CO2 and 95% air.  Unattached cells were 
removed on the following day.  The attached cells were then denoted BMMSCs.  
Cell colonies that formed during culture were identified and removed by gentle 
trypsinization (0.25% trypsin-EDTA).  Trypsin was removed by centrifugation.  
Each colony of BMMSCs was re-seeded in a new culture flask.  Half of the 
culture medium was replaced by a fresh aliquot of medium once every 2 days.  
The BMMSCs were then allowed to grow to about 75% confluence before use.  
Passage 2 cells were used throughout the study.  Attached cells were detached 
by trypsinization and resuspended in fresh culture medium for subsequent 
experiments.   Although the experiments were done using bone marrow 
donated by three different patients, the results are a representative from one 
sample which had consistent cell morphology and a high cell proliferation rate by 
passage 2. 
 
Culture of bone chip-derived osteoblasts (BC-OBs)   
 BC-OBs were obtained from bone chips of the same patients from whom 
bone marrow was taken for the culture of BMMSCs.  The bone chips were 
washed 3 times in HBSS, cut into smaller fragments before being placed in 
tissue culture flasks and cultured under the same conditions as BMMSCs.  Upon 
reaching approximately 75% confluence, the bone chips were removed and the 
cells were washed 3 times with HBSS, trypsinized and reseeded in new tissue 
culture flasks for further expansion.  Passage 2 BC-OBs were used for RT-PCR. 
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Culture of human mesenchymal stem cells (hMSC) (Lonza, USA)   
Human mesenchymal stem cells (hMSC) were seeded into cell culture 
flasks and cultured in a medium comprising Minimal Essential Medium-alpha 
(MEM-α), supplemented with 10% foetal bovine serum (FBS), L-glutamine 
(2mmol/l), penicillin (100 U/ml) and streptomycin sulphate (100  µg/ml), and 
incubated at 37oC in a humidified atmosphere of 5% CO2 and 95% air.  
Unattached cells were removed on the following day.  Half of the culture medium 
was replaced by a fresh aliquot of medium once every 2 days.  The attached 
cells were allowed to grow to about 75% confluence.  Cells colonies that were 
formed were identified and individually removed by gentle trypsinization, seeded 
into a new flask each and allowed to grow to about 75% confluence before being 
used.  Passage 2 hMSCs were used throughout the study.  Attached cells were 
detached by trypsinization and resuspended in fresh culture medium for 
subsequent experiments described below.  Undifferentiated hMSCs were used 
as a negative control in the alkaline phosphatase (ALP) assay. 
 
Culture of human osteoblasts (hFOBs) (ATCC, USA) 
 hFOBs were cultured in a medium comprising a 1:1 mixture of Ham’s F12 
Medium and Dulbecco’s Modified Eagle’s Medium without phenol red, 
supplemented with 10% FBS and 0.3 mg / ml of G418.  The hFOBs were 
maintained at a permissive temperature of 34oC in 5% CO2 in a humidified 
atmosphere.  For differentiation into osteoblasts, the hFOBs were maintained at 
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a restrictive temperature of 39.5oC.  Differentiated osteoblasts were used as a 
positive control in assays for bone-cell differentiation. 
 
Cell attachment      
 Cell attachment on the various titanium substrates was evaluated by 
counting the number of attached cells (BMMSCs or hMSCs) 6 hours after cell 
seeding.  The substrates were placed into a 24-well plate and seeded with cells 
at a density of 5 000 cells / cm2.  The number of attached cells on the substrates 
was evaluated, and compared to the number of attached cells on the bottom of a 
similar well without any titanium substrate (control).  At the time of cell counting, 
unattached cells were rinsed off with PBS.  The attached cells were detached 
with trypsin.  Tryspin was removed by centrifugation. The cells were 
resuspended in an appropriate amount of cell culture medium and counted using 
a haemocytometer. 
 
Cell proliferation    
 Cell proliferation on the substrates was evaluated by counting the number 
of attached cells on days 1, 3, 5 and 7.  The number of attached cells on the 
bottom of a similar well without any titanium substrate was counted at the 
respective points in time and was used as a control.  At each designated point in 
time, the unattached cells were rinsed off with PBS.  Attached cells were 
detached and counted as described above.  The number of attached cells is 
reported as number of cells / cm2. 
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Flow cytometry #  
 Flow cytometry is a technique used in the work described in chapter 3 to 
detect cell surface markers on the BMMSCs to confirm the cell lineage.  The 
procedure is described in chapter 3.  Flow cytometry is also used in chapter 7, to 
rule out the presence of CD133+ cells, which are endothelial progenitors.   
 
Cytotoxicity assay  
 The MTT assay was carried out at day 7 of culture of the cells on the 
different titanium substrates to assess the effect of the substrates on cell viability.  
The assay is based on the conversion of yellow MTT (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) to purple formazan in the mitochondria of 
living cells.  A suitable quantity of MTT reagent was added to the cells at day 7 of 
culture on the different substrates and then incubated for 4 hours at 37oC.  At the 
end of the incubation period, an appropriate amount of solubilization solution 
(supplied in the MTT assay kit) was added to respective cultures and then gently 
mixed on an orbital shaker for one hour at room temperature.  The insoluble 
purple formazan product was dissolved in the solubilization reagent to give a 
purple solution.  The intensity of the colour in each well was measured at 570 nm 
on an absorbance plate reader. 
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Alkaline phosphatase (ALP) assay 
The level of ALP of the cells was assessed using an ALP assay kit.  The 
ALP assay is used in the studies to assess the level of osteoblast differentiation 
from BMMSCs or hMSCs.  This assay relies on the ALP hydrolysis of p-
nitrophenyl phosphate into a yellow product, the intensity of which was measured 
at 405nm on an absorbance plate reader.  Briefly, BMMSCs or hMSCs were 
seeded onto the substrates at a density of 5,000 cells / cm2.  At day 7 of culture, 
the cell layers were washed with HBSS and gently scraped off from the surfaces 
of the substrates.  HBSS was removed by centrifugation and cell lysis buffer was 
then added to the cells. The cells were sonicated to disrupt the cell membranes.  
After sonication, cellular debris was removed by centrifugation and aliquots of the 
cell lysates were collected for the analysis of the ALP activity and the 
quantification of total protein level.  The assay was carried out at room 
temperature.  For each sample well of a 96-well plate, 50µl of the respective cell 
lysate was added.  A further 150 µl of the kit’s working reagent comprising 5 mM 
of magnesium acetate and 10 mM of p-nitrophenyl phosphate were then added 
to each sample well.  The colour intensity of the reaction mixture was measured 
at 4 minute intervals.  The ALP activity of each sample was calculated according 
to a formula provided in the kit.  The readings at the 20-minute interval were used 
to determine the respective levels of ALP activity.  ALP activity was determined 
as the rate of p-nitrophenol liberation from p-nitrophenyl phosphate, normalized 
with respect to the total protein content obtained from the same cell lysate, and 
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expressed as number of IU of p-nitrophenol formation per minute per milligram of 
total proteins (IU min-1 mg-1 protein).  
 
Reverse transcription-polymerase chain reaction (RT-PCR) 
 RNA was extracted from cells on day 10 of culture using the NucleoSpin®  
RNA / Protein isolation kit (Macherey-Nagel, GmbH, Germany) according to the 
manufacturer’s instructions.  Each sample of RNA was diluted 50X with DEPC 
(diethypyrocarbonate) water and the RNA concentration was measured using the 
NanoDrop ND1000 spectrophotometer.  1 µg of each sample of total RNA was 
used for the RT-PCR reaction.  Reverse transcription of mRNA to cDNA and 
subsequent cDNA amplification was done using the TITANIUM™ One-step RT-
PCR Kit (Clontech Laboratories, Inc., US), through one cycle at 50oC for 1h and 
94oC for 5 minutes.  This was followed by 32 cycles at 94oC for 30 seconds, 60oC 
for 30 seconds and 68oC for 1 minute, with a final extention at 68oC for 2 
minutes.  The expression of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was used to check RNA integrity.  The amplified products were 
subjected to electrophoresis in a 2% agarose gel and stained with ethidium 
bromide (Sigma-Aldrich, Singapore).  Cells grown on the titanium substrates 
were compared with BC-OBs or human osteoblasts (hFOBs), and untreated 
BMMSCs or hMSCs, both cultured in normal tissue culture flasks.  BC-OBs or 
hFOBs were used as a positive control while BMMSCs or hMSCs were used as a 
negative control.  Densitometry was done to quantify the relative levels of the 
bone-related genes, normalized to the respective levels of GADPH.   
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Alizarin red staining 
 Cells were grown on the titanium substrates for 21 days and removed by 
trypsinization, then re-seeded into individual wells of a new 24-well plate.  At 48 
hours after re-plating, the cells were stained with 1% alizarin red S for 2 minutes 
and then washed with PBS.  The stained cells were observed under a light 
microscope to detect intracellular calcium deposits. 
 
Statistical analysis 
 The results were assessed statistically using one-way analysis of 























Chapter 3   
A Preliminary Study 
Human bone marrow-derived mesenchymal stem cells differentiation into 
osteoblasts on titanium with surface-grafted chitosan and immobilized 
















 Introduction  
 Circulating mesenchymal stem cells (MSC) are known to migrate and 
home to various organs to mediate tissue repair [69, 118].  Similarly, it is possible 
that circulating bone progenitor cells can home to a bone implant and 
differentiate into bone-forming cells, eventually leading to osseointegration with 
the prosthesis.  However, bacterial infection following surgical implantation of 
biomaterials and devices poses a risk to an implant.  It has been shown that 
titanium (Ti) with surface-grafted chitosan (CS) prevents bacterial adhesion, the 
mechanism of which has been proposed to be due to the interaction between the 
oppositely charged bacterial cell wall and the CS [119, 120]. This interaction 
results in a change in bacterial membrane permeability, leading to the fatal 
leakage of cellular contents.  Previous work has shown that bone morphogenetic 
protein-2 (BMP2)-adsorbed onto titanium porous oxide implant surfaces had an 
osteoconductive effect which was surface- and dose-dependent [121].  The 
incorporation of BMP2 into biomimetic coatings like calcium phosphate has been 
shown to result in the formation of bone cells at the implant site [120, 121].  
However, others have also reported that BMP2 immoblized onto implants does 
not increase bone formation [122].  In the present study, the aim was to 
investigate if BMP2 immobilized onto bacteria-resistant chitosan-grafted titanium 
substrate will enhance BMMSC adhesion on the substrate surface and further 




Materials and methods    
Materials     
 Materials and methods specific to this chapter are described below.  All 
the other materials and methods used in this chapter are described in Chapter 2 
(General materials and methods).   
 
Preparation of chitosan-grafted titanium substrate with immobilized BMP2 (Ti-
CS-BMP2 substrate) 
Ti foils of 0.52-mm thickness were cut to a size of 1 cm X 1 cm, and 
cleaned with sandpaper, followed by sonication sequentially in Knoll’s reagent 
(4.0% HF, 7.2% HNO3, 88.8% water), dichloromethane, acetone and water.  
After surface passivation in 40% HNO3, dopamine was anchored to the surface 
of the Ti substrates by immersion in a 1 mg / ml solution of dopamine at room 
temperature in the dark overnight, as described elsewhere [123].  Unbound 
dopamine was washed off with copious PBS and the substrates were air dried in 
a sterile environment.  Subsequently, the substrates were immersed in a stirred 
3% glutaraldehyde solution at room temperature overnight.  Glutaraldehyde 
serves as a cross-linker, providing the reactive aldehyde groups for covalently 
bonding dopamine and CS.  Unbound glutaraldehye was removed by rinsing the 
substrates in water.  CS was dissolved in a 0.1% dilute acetic acid to a 
concentration of 5 mg / ml.  The glutaraldehyde-treated substrates were then 
immersed in the CS solution.  Imine bonds are formed between the aldehyde 
groups on the Ti surface and the primary amino groups at the C-2 position of CS.  
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The resulting substrates were then washed with water and dried under vacuum.  
Some of the chitosan-grafted Ti substrates were then individually coated with 
BMP2 at a concentration of 50 µg / ml and allowed to air dry in a sterile 
environment.    Following which, the substrates were rinsed 3 times with sterile 
PBS to remove unattached BMP2 and left to air dry in a sterile environment 
before use.  The present author used a BMP2 concentration of 50 µg / ml to coat 
the titanium substrates to ensure that the growth factor was adequately adsorbed 
onto the substrate surface.  The substrates are denoted Ti (pristine titanium), Ti-
CS (chitosan-grafted Ti) and Ti-CS-BMP2 (BMP2-coated, chitosan-grafted Ti) in 
subsequent discussions.  Fig. 3.1a is a schematic to illustrate the preparation of 
the substrates.  Fig. 3.1b is a photograph of the sterilized finished substrates 





































































 After the preparation of the Ti-CS-BMP2 substrates, the following were 
subsequently done, the procedures of which are described in chapter 2: 
Stability and surface density of BMP2 on the Ti-CS-BMP2 substrate 
Culture of BMMSCs    
Culture of BC-OBs   
Cell attachment 
BMMSCs attached on the Ti, Ti-CS and Ti-CS-BMP2 substrates 
will subsequently be denoted Ti cells, Ti-CS cells and Ti-CS-BMP2 
cells respectively. 
Cell proliferation 
Fig. 3.1b.  Photograph of finished Ti-CS-BMP2 substrates in 




 Flow cytometry was done to confirm the cell lineage of the BMMSCs prior 
to further work.  The BMMSCs were detached by gentle trypsinization.  The 
detached cells were resuspended and incubated in PBS with 2% FBS for 10 
minutes in an ice bath.  1µl each of CD44-FITC, CD105-PE, CD271-FITC, CD34-
FITC and CD45-FITC antibodies was added to the cells suspended in 100µl of 
PBS with 2% FBS each in separate tubes. The tubes were incubated for 10 
minutes in an ice bath in the dark.  The cells were then washed and resuspended 
in 1 ml of PBS, and analysed using flow cytometry.  10,000 events were collected 
for the analysis of each marker. 
 After the flow cytometry, further work was done to check for any adverse 
effects that the substrate may have on the attached cells.  Work was also done to 
assess the osteogenic potential of the Ti-CS-BMP2 substrates.  The procedures, 
listed below, for the above mentioned work are described in chapter 2: 
Cytotoxicity    
ALP assay   
 RT-PCR 





Results    
Stability and surface density of adsorbed BMP2 on Ti-CS-BMP2 substrates 
 Other researchers have physically modified the surface of the titanium 
substrate and allowed BMP2 to be adsorbed onto the surface.  Upon immersion 
of the substrate in a solution, only a small percentage of the initially adsorbed 
BMP2 remained firmly attached to the substrate surface [5].  In this study, 
chitosan has been covalently linked onto the surface of titanium. These 
substrates were then immersed in a solution containing a high concentration of 
BMP2 to allow sufficient BMP2 to be adsorbed onto the substrate surface.  BMP2 
adsorption on the Ti-CS substrates is probably via strong electrostatic interaction.  
It can be expected that most of the BMP2 molecules would be detached from the 
substrate surface upon immersion in a liquid.  It was found that only about 1%, or 
500 ng of the initial coating solution concentration of 50 µg, was firmly attached 
onto the substrate surface.  Approximately 81% of the 500 ng of BMP2 that was 
initially attached on day 0 remained attached to the substrate surface on day 1.  
The attached BMP2 was slowly released into solution over time, at a rate of 
about 2% per day from day 3 to day 7, as is shown by the results of the surface 
density assessment in Fig. 3.2.  From Fig. 3.2, it can also be seen that the BMP2 
rate of release was not consistent from day 0 to the start of day 3.  This could 
probably be due to the overcrowding of BMP2 molecules on the substrate 
surface, resulting in some of the BMP2 molecules being loosely attached.  By 
day 7, the amount of attached BMP2 was still more than 50% of the initial coating 
density, suggesting that enough BMP2 can remain attached on the Ti-CS surface 
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for a length of time, and released slowly to support osteoblast differentiation.  
The surface density of BMP2 adsorbed onto the Ti-CS surface is comparable to 








Fig. 3.2.  Data reported as percentage of BMP2 that remained 
adsorbed on the Ti-CS substrate (n = 2) (p < 0.05).  Error bars 
represent the standard deviations of each group.  About 70% 
of the initial coating of BMP2 remained attached to the Ti-CS 
substrate surface after 7 days of submersion in PBS, indicating 
that BMP2 can potentially remain attached for a sufficient 
period of time to enhance osteoblast differentiation.  
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Cell attachment and proliferation 
The number of BMMSCs attached on the various titanium surfaces was 
assessed 6 h after cell seeding, and compared to the control, where the cells  are 
directly attached to the bottom of the culture well (Fig. 3.3).  Cell attachment on 
Ti-CS substrates was comparable to that in the control (without any titanium 
substrate), while the number of cells attached to the pristine Ti substrate was 
less compared to that on either the Ti-CS substrate or in the control.  This 
suggests that the chitosan that is grafted onto the titanium enhances initial cell 
attachment.  However, the Ti-CS-BMP2 substrates had the least number of 
attached cells.  This can probably be attributed to the fact that the adsorbed 
BMP2 molecules occupied a proportion of the available area on the chitosan-
grafted titanium surface, altering its surface topology.  Substrate surface topology 
is known to affect cell attachment [124].  Cell proliferation progressed steadily 
over the following 7 days of culture, as shown in Fig. 3.5.  Except for the control 
on day 7, the cell proliferation rates were not significantly different on all the 
titanium substrates and in the controls (p < 0.05).  This apparent anomaly could 
be due to the fact that cells on the substrates were undergoing differentiation, as 
differentiating cells are known to slow down in proliferation rate or even leave the 
cell cycle [125].  Others have shown that cell attachment is significantly affected 
by the presence of phosphate and apatite groups on the titanium surface [126].  
This suggests that the presence of certain types of molecules on the titanium 
substrate surface can affect the degree of cell attachment.  Besides the presence 
of certain preferred molecules, the technique employed in applying coatings on a 
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titanium substrate can alter the substrate surface topology, and hence, cell 
attachment efficiency [124].  Despite much work done, there is still no unanimous 
agreement as to the optimal surface topology of an implant surface [127].  
However, there is a positive correlation between implant surface topology and 
bone attachment [127].  In comparison, the chitosan on the Ti-CS substrate is a 
stable, covalently attached layer which should confer anti-bacterial properties to 
the titanium substrate for an extended period of time, while promoting cell 







Fig. 3.3.  The number of attached BMMSCs on each type of 
titanium substrate (n = 2) (p < 0.05) was evaluated after 6 
hours.  Error bars represent the standard deviations of each 
group.  As shown, BMMSCs can adhere to the titanium 
substrates as effectively as on the plastic surface of culture 
flasks, suggesting that bone implants constructed with these 
substrates can possibly support BMMSC adhesion on the 
prosthesis, where further cellular developments can occur. 
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Flow cytometry 
 Passage 2 BMMSCs were subjected to flow cytometry analysis after being 
separately stained with CD271, CD44, CD105, CD34 and CD45 antibodies to 
assess their lineage (Table 3.1).  About 64% of the cells were CD44+ while 
approximately 86% of them were CD105+.  About 1.3% of CD34+ cells and 1.1% 
of CD45+ cells were present among the BMMSCs.  The rare population of 
CD271 cells which has been described as one of the most specific markers of 













Table 3.1.  This analysis shows the profile of the surface 
markers of the bone marrow stromal cells. 
Flow cytometry analysis of these passage 2 BMMSCs shows 
the presence of mesenchymal stem cell markers CD271, CD44 
and CD105, suggesting that there is a population of progenitor 
cells in bone marrow that can possibly contribute to osteoblast 
differentiation and osseointegrate with the titanium substrates.  
A small fraction of CD34+ and CD45+ haematopoietic cells 
was present among the BMMSCs.  
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Cytotoxicity 
 Cell viability on the 3 types of substrates was assessed using the MTT 
assay (Fig. 3.4), to give an indication of the effect of the substrates on the 
survival and proliferation of the attached cells.  The assay was done on day 7 of 
culture and the results suggest that all the 3 types of titanium substrates do not 
seem to be cytotoxic to the cells, and can support cell growth and proliferation 









Fig. 3.4.  The MTT assay shows that the three types of 
titanium substrates (n = 2) do not adversely affect cell viability, 
suggesting that these substrates are probably not cytotoxic in 
vivo, and can possibly be used to fabricate bone implants.  














Fig. 3.5.  The ability of the titanium substrates to support cell 
proliferation was assessed by counting the number of attached 
BMMSCs on each type of substrate (n = 2) on days 1, 3, 5 and 
7.  The cell proliferation rates are consistent on all the three 
types of substrates.  By day 7, most of the cells on the 
substrates are probably differentiating, hence the slow-down in 
proliferation rates as compared with that in the control (denoted 
by *).  Error bars represent the standard deviations of each 
group. 
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Alkaline phosphatase activity 
 The results in Fig. 3.6 indicate that osteoblast differentiation occurred on 
all the substrates, with the ALP activity of the cells on the various substrates in 
the ascending order Ti, Ti-CS, and Ti-CS-BMP2.  Chitosan has been shown to 
enhance the ALP activity of osteoblasts [130, 131].  The results show that 
although there was a higher ALP activity in the Ti-CS cells compared with the Ti 
cells, the increase was not significant.  However, Ti-CS-BMP2 cells showed a 
significantly higher ALP activity over both Ti cells and Ti-CS cells (p < 0.05).  
Thus, the results suggest that CS and BMP2 on the Ti-CS-BMP2 substrate 
surface may have a synergistic effect in enhancing osteoblast differentiation from 
BMMSCs.  Based on the above results, RT-PCR was carried out using BMMSCs 
























Fig. 3.6.  ALP activity (Day 7) in the cells attached to each type 
of titanium substrate (n = 2) indicates osteoblast differentiation.  
Although cells on the Ti-CS substrates had a higher ALP activity 
than those on the Ti substrates, this was not significant.  Only 
cells on the Ti-CS-BMP2 substrates show a significantly higher 
ALP activity than cell on either of the other 2 types of substrates 
(denoted by *), indicating that CS and BMP2 may synergistically 
work to enhance BMMSC differentiation into osteoblasts.  In 
contrast, BMMSCs cultured in normal tissue culture flasks 
showed almost no ALP activity.  The ALP activity of BC-OBs 
serves as a positive control.  Error bars represent the standard 
deviations of each group.  
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RT-PCR 
 RT-PCR was carried out to assess the expression of the genetic markers, 
Runx2, collagen type I (Col I) and osteocalcin (OCN), to confirm osteoblast 
differentiation on the Ti-CS-BMP2 substrate (Fig. 3.7a).  The results were 
compared with those from BC-OBs and untreated BMMSCs cultured in normal 
tissue culture flasks.  In addition, BC-OBs were also assessed for the expression 
of endogenous BMP2, a key growth factor involved in bone formation, to confirm 
the bone cell lineage of the BC-OBs.  Fig. 3.7b shows the relative levels of 
expression of the 3 genes in BC-OBs and Ti-CS-BMP2 cells, normalized to the 






































Fig. 3.7a and Fig. 3.7b.  RT-PCR of Runx2, Col I and OCN suggests that Ti-
CS-BMP2 cells are undergoing osteoblast differentiation, unlike BC-OBs 
(positive control), which are mature osteoblasts.  This is evident from the 
comparatively higher level of Runx2, indicating a higher transcription level of 
this gene, and the relatively lower levels of Col I and OCN, indicating that the 
Ti-CS-BMP2 cells are not fully differentiated osteoblasts yet.  Conversely, 
untreated BMMSCs cultured in plastic tissue culture flasks (negative control) 
do not differentiate and hence have no detectable level of bone-related 
markers except for Col I.  
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RUNX2 
(NM_004348)  
Forward   tttgcactgggtcatgtgtt 





    
Collagen I 
(NM_000088) 
Forward   ccaaatctgtctccccagaa 
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(NM_001200) 
Forward   cccagcgtgaaaagagagac 
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(NM_002046) 
Forward   gagtcaacggatttggtcgt 
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Alizarin Red staining 
 The Ti-CS-BMP2 cells were stained with Alizarin Red S to detect calcium 
deposits in the cells.  Fig. 3.8a shows some of the positively-stained cells, while 



















































Fig. 3.8.  (a) Ti-CS-BMP2 cells that stain positive for the presence of calcium 
deposits with alizarin red S indicate osteoblast differentiation.  (b) Untreated, 




 MSCs have been reported to retain their undifferentiated phenotype and 
remain capable of osteogenic differentiation during ex vivo expansion through 
multiple passages [132].  Their surface marker expression profiles remain 
consistent, and their gene expression profiles do not change significantly during 
long-term expansion [132].  The well-established MSC markers, CD44 and 
CD105, used to confirm the MSC lineage of the BMMSCs in the present study 
reveal that there is a population of relatively undifferentiated progenitors that can 
possibly contribute to osteoblast differentiation [132-134].  In addition, a small 
population of the cells were found to be CD271+.  CD271 is one of the most 
specific and novel markers of BMMSCs [128].  CD271+ cells are highly 
proliferative, and possess multilineage differentiation potential [129, 134, 135].  
Unfortunately, CD271+ cells are rare in a population of bone marrow-derived 
cells, and would have to be immunomagnetically isolated, and then expanded in 
vitro.  Thus, a relatively large volume of bone marrow would have to be extracted 
in order that a feasible number of CD271+ cells can be magnetically isolated to 
constitute the starting cells for in vitro expansion.   
 While osteoblast differentiation from BMMSCs may occur on the surface 
of titanium substrates, it is paramount that BMMSCs must first be able to firmly 
attach to the substrate surface. This is to ensure that osseointegration of a bone 
implant can take place in vivo.  MSCs are known to adhere strongly to plastic 
surfaces and this characteristic has enabled them to be easily isolated and 
investigated for potential therapeutic applications [136].  The patient-derived 
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BMMSCs used in the present study also similarly adhere to plastic surfaces and 
to the various titanium substrates.  Firm cell attachment is evidenced by the 
prolonged trypsinization required to detach them from the substrates.   Together 
with the consistent cell proliferation rates, this indicates that BMMSCs can be a 
potential source of progenitors to initiate osseointegration with functionalized 
titanium-based implants in vivo.  However, such surface-modified implants must 
be biocompatible.  The results of the MTT assay show that the titanium-based 
substrates do not adversely affect cell viability, indicating that these substrates 
probably would not be cytotoxic in vivo.    
An assessment of the ALP activity of the cells on the various types of 
substrate surfaces on day 7 of culture suggests that osteoblast differentiation can 
possibly occur soon after cell attachment.  While others have used calcium 
phosphate-coated, collagen-coated, or chondroitin sulphate-coated titanium to 
enhance the retention of BMP2 on the substrate surface, BMP2  in this case was 
allowed to be adsorbed onto the chitosan-grafted titanium substrates. [122, 137, 
138].  Besides being able to promote osteoblast differentiation, chitosan also 
possesses anti-bacterial properties [139-142].  Thus, it can be hypothesized that 
chitosan and BMP2 would act synergistically to improve osteoblast differentiation 
on titanium surfaces.  Based on the results of the ALP assay, it would be 
reasonable to expect that the Ti-CS-BMP2 substrates would be the most 
osteogenic among the 3 types of titanium substrates.  The expression levels of 
three bone genetic markers in the BMMSCs grown on Ti-CS-BMP2 substrates 
was then assessed.  RT-PCR was carried out to assess the expression levels of 
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three key bone markers, Runx2, Col I and OCN.  Runx2 is the trasnscription 
gene of the osteoblast specific protein, osteocalcin.  Together, Runx2 and OCN 
are the key regulators of osteoblast differentiation and function [143-145].  Runx2 
is regulated by a number of factors including bone morphogenetic protein (BMP).  
It functions as a scaffold protein for nucleic acids and regulatory factors involved 
in skeletal gene expression.  Osteocalcin is the major noncollagenous protein of 
bone matrix [146].  Interestingly,  besides being used as a biomarker of 
osteoblast differentiation, this gene has been implicated in human osteoarthritis 
and its presence could possibly mark the stage of the development of this 
disease at a point of dysregulation of cellular behaviour and failure of repair 
mechanisms [146].  Thus, the detection of OCN in the serum may potentially be 
used as a clinical indicator of the need for a bone implant.     Collagen I is the 
major constituent in bone extracellular matrix [147].  Cells of the bone lineage 
express Col I in all their developmental stages.  Collagen I interacts with the α2β1 
integrin receptor on the cell membrane to mediate transduction of extracellular 
signals into the cell [148].  The interruption of this collagen-integrin interaction 
inhibits  osteoblast differentiation from bone marrow cells [148].  The RT-PCR 
results show that these three key genes were expressed in the Ti-CS-BMP2 
cells, and only Col I was expressed in the untreated BMMSCs, indicating that the 
Ti-CS-BMP2 substrate promotes osteoblast differentiation in the BMMSCs that 
adhered to its surface.  A densitometry of the band intensities of Runx2, Col I and 
OCN suggests that the Ti-CS-BMP2 cells were in the early stages of osteoblast 
differentiation (Fig. 3b).  This is evident from the relatively lower levels of Col I 
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and OCN in the Ti-CS-BMP2 cells as compared with those from the BC-OBs.  
Furthermore, the relatively higher level of the transcription factor, Runx2, in the 
Ti-CS-BMP2 cells suggests a higher gene transcription activity level of bone-
related genes than that in the BC-OBs.  Additionally, the BC-OBs were assessed 
for the expression of endogenous BMP2, which is a key gene in bone cells, as 
BMP2 also serves to regulate the Runx2 gene.  Finally, the Ti-CS-BMP2 cells 
were stained with Alizarin Red S to detect calcium deposits in the cells.   
Besides chemically modifying the substrate surface, others have also 
physically modified the titanium substrate surface to enhance the adsorption of 
BMP2 [121].  While most of these modified surfaces have been reported to 
support osteoblast differentiation, others have also reported that immobilized 
BMP2 on titanium substrates with biomimetic coatings does not enhance bone 
formation [122]. 
   
Conclusion   
Circulating progenitor cells are known to home to various organs to repair 
injured tissues or to routinely replace old cells and maintain tissue integrity. 
Similarly, circulating progenitor bone cells can possibly home to a bone implant, 
differentiate, and eventually osseointegrate with the prosthesis. Osseointegration 
of bone cells with the prosthesis can help to reduce the risk of implant failure due 
to constant movement between bone tissue and implant surface.  The aim of this 
preliminary study is to investigate if Ti-CS-BMP2 will enhance BMMSC adhesion 
onto the substrate surface and further induce their differentiation into osteoblasts. 
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The results show that the Ti-CSBMP2 substrate is able to retain adsorbed BMP2, 
and is capable of slow release of this growth factor. Despite the lesser number of 
BMMSCs initially attached onto the Ti-CS-BMP2 substrates and consequently 
the lower level of cell proliferation, Ti-CS-BMP2 cells had the highest level of ALP 
activity. RT-PCR results show that Ti-CSBMP2cells had a relatively higher level 
of transcription activity of Runx2, compared with that of bone cell-derived 
osteoblasts (BC-OB), an indication that the BMMSCs were actively differentiating 
into osteoblasts. Finally, Alizarin Red staining reveals the presence of calcium 
deposits in the differentiated cells. Hence, Ti-CS-BMP2 substrates possess an 
osteoconductive effect and can possibly be used to fabricate bone implants that 
can osseointegrate with host bone tissue. 
The method of immobilizing BMP2 onto chitosan-grafted titanium surfaces 
in the present study is convenient and effective in promoting BMMSC-derived 
osteoblast differentiation.  Although only a small proportion of the initial amount 
of BMP2 used for adsorption onto the chitosan-grafted titanium surface was 
firmly attached, this amount was sufficient to promote osteoblast differentiation.  
Nevertheless, one very distinct advantage of the chitosan-grafted titanium 
substrates is their bacteria-resistant property.  The Ti-CS-BMP2 substrate 
therefore has the potential to be used to fabricate anti-bacteria, osteoconductive 
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 Titanium and its alloys are widely used in orthopaedic and dental implants.  
Although titanium surface is biocompatible and possesses bioactivity, the 
bioactivity level is insufficient to encourage osseointegration of implant with host 
bone tissue [149].  Failure of an implant to osseointegrate with host bone tissue 
can ultimately result in implant failure [149].  Past attempts have thus been made 
to activate titanium surface to facilitate the attachment and proliferation of bone 
cells, so that osseointegration may occur.  Currently, the focus is on the 
biochemical modification of titanium surface with the incorporation of bioactive 
molecules [150].  As mentioned in chapter 3, while others have incorporated 
BMP2 into biomimetic coatings and successfully induced the formation of bone 
cells at the implant site, there are also contradictory reports [122].   
 Besides the difficulties encountered in the surface modification of titanium, 
another major clinical problem is titanium implant-related infections.  Bacteria 
attached to an implant surface during surgery forms a resistant biofilm which 
confers protection upon the bacteria by delaying the action of anti-microbial 
agents [4].  Bacterial infection at an implant site can eventually result in localized 
bone destruction, leading to implant failure.  A failed implant may then need to be 
removed, a costly and painful process for the patient. 
Thus, a biomaterial which possesses osteoconductive and anti-bacterial 
properties would have the potential to be used for the fabrication of longer-lasting 
bone implants.  In the present study, work is done to assess the effectiveness of 
a surface-modified titanium alloy in promoting osteoblast differentiation.  Previous 
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work has shown that the dextran-grafted titanium (Ti-Dex) substrate possesses 
anti-bacterial properties [114].  The Ti-Dex substrate has been further 
functionalized with bone morphogenetic protein-2 (BMP2) to enhance osteoblast 
functions.  The present study shows that hMSCs can adhere to the Ti-Dex-BMP2 
substrate, proliferate, and differentiate into osteoblasts.  The methodology and 
results of the various experiments in this study, which are discussed in chapter 5,  
will be considered in the context of the anti-bacterial mechanism and the 
complexity of the substrate fabrication procedure, and compared similarly to that 
of the study in chapter 3, in order to select either the Ti-CS-BMP2 substrate or 











Materials and Methods    
Materials    
 Materials and methods specific to this chapter are described below.  All 
the other materials and methods used in this chapter are described in Chapter 2 
(General materials and methods). 
In order to avoid implicating factors due to patient variability, patient bone 
marrow-derived mesenchymal stem cells and patient bone chip-derived 
osteoblasts were not used in the present study.  Instead, appropriately 
characterized human mesenchymal stem cells (hMSC) and human osteoblasts 
(hFOB) were purchased from Lonza, USA, a commercial source and used for all 
the experiments.     
 
Preparation of the Ti-Dex-BMP2 substrate    
Ti foils of 0.52-mm thickness were cut to a size of 1 cm X 1 cm, and 
cleaned with sandpaper, followed by sonication sequentially in Knoll’s reagent 
(4.0% HF, 7.2% HNO3, 88.8% water), dichloromethane, acetone and water.  
After surface passivation in 40% HNO3, dopamine was anchored to the surface 
of the Ti substrates as described elsewhere [123].  The Ti substrates were 
immersed in a 1 mg / ml solution of dopamine overnight in the dark.  Unattached 
dopamine was washed off with copious amounts of ultra-pure water and the 
substrates were dried under nitrogen flow.   
Dextran was oxidized using periodate oxidation to produce aldehyde 
groups  [151, 152].  Briefly, 2.18 g of sodium periodate (NaIO4) were added to 50 
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ml of dextran solution (33.33 mg / ml).  The reaction mixture was continuously 
stirred for 24 h at room temperature, protected from light.  The resulting solution 
was purified by exhaustive dialysis against water at 4oC.  The purified dextran 
solution was lyophilized and stored at 4oC.   
The immobilization of dextran onto the Ti substrates was carried out using 
a reductive amination process [49, 133, 134].  Oxidized dextran was dissolved in 
0.1 M PBS to a concentration of 2 mg / ml.  Dopamine-modified Ti substrates 
were individually placed in each well of a 24-well plate.  Two ml of the dissolved 
dextran solution was added to each well and the substrates were incubated 
overnight at room temperature, protected from light.  After incubation, the 
reaction mixture was decanted from the wells and replaced with freshly prepared 
sodium borohydride (NaBH4) solution (0.1 M) to reduce the Schiff bases formed 
to secondary amine bonds.  Any free unreacted aldehyde groups on the oxidized 
dextran chain would be reduced to hydroxyl groups.  The substrates were 
incubated for 2 h with slight shaking.  The NaBH4 solution was then removed and 
the substrates were gently rinsed with ultra-pure water to remove unbound 
dextran, and allowed to dry before proceeding to the subsequent steps.   
The dextran-grafted Ti substrates were further functionalized with BMP2 
through a second reductive amination reaction.  After treatment with 0.1 M NaIO4 
at room temperature for 2 h, the substrates were washed with steirle water and 
allowed to dry.  The substrates were then incubated in a BMP2 solution (50 µg / 
ml) overnight at room temperature.  The BMP2 solution was then decanted and 
replaced with freshly prepared 0.1 M NaBH4 and left for 2 h.  The substrates 
 95 
were then rinsed with water containing 0.1% sodium dodecyl sulphate to remove 
the unreacted BMP2.   After which, the substrates were incubated overnight in 
0.1 M ethanolamine in PBS to quench any unreacted hemiacetal groups that 
could immobilize serum matrix and cell surface proteins and thus promoting non-
specific cell adhesion [43].  The substrates were allowed to dry before use.  In 
subsequent discussions, the substrates are denoted as Ti-Dex-BMP2. 
 After the preparation of the Ti-Dex-BMP2 substrates, the following were 
subsequently done, and the procedures are described in chapter 2: 
Stability and surface density of BMP2 on the Ti-Dex-BMP2 substrate 
Culture of hMSCs      
Culture of hFOBs 
Cell attachment 
hMSCs attached on the Ti, Ti-Dex and Ti-Dex-BMP2 substrates will 






Differentiation of hMSCs into osteoblasts on the Ti-Dex-BMP2 substrate 
The Ti-Dex-BMP2 substrate has been shown to support cell adhesion and 
is therefore not cytotoxic [114].  The substrates were placed into a 24-well plate 
and seeded with hMSCs at a density of 10 000 cells / cm2.  Two ml of osteogenic 
medium comprising normal hMSC culture medium supplemented with 10 nM 
dexamethasone, 7 mM β-glycerophosphate and 0.2 mM ascorbic acid were 
added to each well.  Half of the medium was removed and replaced with fresh 
medium after every 2 days.  The cells were allowed to differentiate for 7 days 
before being used for the following subsequent experiments, to assess the 
osteogenic potential of the Ti-Dex-BMP2 substrates.  The procedures, listed 
below, for the above mentioned work is described in chapter 2: 
ALP assay  
 RT-PCR 
 Alizarin Red staining  
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Results     
Stability and surface density of adsorbed BMP2 on Ti-Dex-BMP2 substrates 
Titanium has previously been modified to allow BMP2 to be adsorbed onto 
the surface.  Upon immersion of the substrate in a solution, only a small 
percentage of the initially adsorbed amount of BMP2 remained firmly attached to 
the substrate surface [121, 153].  In the current study, oxidized dextran was 
covalently linked onto dopamine coated Ti (Ti-Dex) substrates.  BMP2 was then 
covalently linked to the Ti-Dex substrate surface.  It is expected that chemical 
attachment would help to retain a relatively higher percentage of BMP2 on the 
substrate.  About 2.33%, or 1.164 µg of the initial coating solution concentration 
of 50 µg, were firmly attached onto the substrate surface.  There was a loss of 
2% of the BMP2 from the substrate surface from day 0 to day 1 which could 
probably be attributed to the detachment of some loosely bound BMP2.  
However, by day 14, the surface density was almost 95%, indicating the stability 
of the covalently bound BMP2 molecules on the substrate, which contrasts 
sharply with adsorbed BMP2 on the Ti-CS substrate described in chapter 3.  This 
suggests that BMP2 can be stably retained on the substrate for a substantially 
















Fig. 4,1.  The number of attached hMSCs on each type of titanium 
substrate (n = 2) was evaluated 6h after cell seeding.  Error bars 
represent the standard deviations of each group.  Adhesion of hMSCs 
to the Ti and Ti-Dex-BMP2 is comparable to that on plastic culture 
flasks (control), suggesting that bone implants constructed with these 
substrates can possibly support hMSC adhesion and further cellular 
developments.  Immobilized BMP2 restores the adhesion capability of 
hMSCs on the Ti-Dex surface. 
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Comparison of cell attachment on Ti-CS, Ti-
























































Fig. 4,1a.  A comparison of the number of cells attached on the Ti-CS 
and Ti-CS-BMP2 (done in chapter 3), and, Ti-Dex and Ti-Dex-BMP2 
substrates show that only the Ti-Dex substrate had a significant 
decrease in the number of attached cells, suggesting that dextran 
prevents initial cell attachment.  Error bars represent the standard 
deviations of each group.   
 100 
Cell attachment and proliferation 
The number of hMSCs attached on the substrate surfaces was assessed 
6 h after cell seeding, and compared to the control, where the cells were directly 
attached to the bottom of the culture well (Fig. 4.1).  The results show that cell 
attachment on the Ti-Dex substrate was only about 20% of that on the pristine Ti 
substrate.  This is consistent with the results obtained by others [43].   The low 
cell adhesion rate could be due to the repulsion of cells from the negatively-
charged dextran coat on the Ti substrate surface.  However, cell attachment was 
considerably enhanced on the Ti-Dex-BMP2 substrate surface.  This suggests 
that BMP2 possesses the ability to enhance cell attachment on a surface that 
otherwise does not promote initial cell attachment.  Firm cell attachment on the 
substrate surface is a prerequisite for osteoblast differentiation, and 
subsequently, osseointegration to occur.  The increased cell attachment in the 
presence of BMP2 could also be due to the altered substrate surface topology 
following the attachment of BMP2.  Substrate surface topology and the type of 
molecules attached on the substrate is known to affect cell attachment [106, 
108].  The technique employed in coating a substrate is also known to alter the 
substrate surface topology and hence the initial cell attachment efficiency [124].  
The results of the cell attachment assay are comparable with those of the Ti-CS-
BMP2 substrate (Fig. 4.1a).  Although the cell adhesion rates on the chitosan 
surface of the Ti-CS substrate is higher than that of BMP2 on the Ti-CS-BMP2 
and Ti-Dex-BMP2 substrates, BMP2 has the dual advantage of promoting cell 
adhesion and enhancing bone cell differentiation (Fig. 4.1a).    
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Cell proliferation progressed steadily over the following 7 days of culture, 
as shown in Fig. 4.2.  On day 7, the cell proliferation rate in the control was 
significantly higher than that on all the titanium substrates (p < 0.05).  
Conversely, cell proliferation on the Ti and Ti-Dex-BMP2 substrates by day 7 had 
noticeably decreased (Fig. 4.2). 
   
 
 
Fig. 4.2.  The ability of the titanium substrates to support cell 
proliferation was assessed by counting the number of attached 
hMSCs on each type of substrate (n = 2) on days 0, 3, 5 and 7.  The 
cell proliferation rates are consistent on all the substrates except on 
Ti-Dex.  By day 7, most of the Ti cells and Ti-Dex-BMP2 cells are 
probably differentiating, hence the slow-down in proliferation rates as 
compared with that in the control (denoted by *).  Error bars represent 
the standard deviations of each group. 
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Alkaline phosphatase activity 
 The results in Fig. 4.3 indicate that osteoblast differentiation occurred on 
both the Ti and Ti-Dex-BMP2 substrates. The ALP activity of the Ti-Dex-BMP2 
cells was significantly higher than that of the Ti cells.  Based on this result, RT-






















Fig. 4.3.  ALP activity in the cells attached to each type of titanium 
substrate (n = 2) indicates osteoblast differentiation.  Ti-Dex-BMP2 
cells show a significantly higher ALP activity than that of the Ti cells 
(denoted by *), indicating that BMP2 retains its osteogenic inductive 
properties after immobilization on the substrate surface.  In contrast, 
hMSCs cultured in plastic culture flasks and on Ti-Dex show almost 
no ALP activity.  The ALP activity of hFOBs and hMSCs serve as the 
positive and negative controls respectively.  Error bars represent the 




 RT-PCR was carried out to assess the expression of the genetic markers, 
Runx2, collagen type I (Col I) and osteocalcin (OCN), to confirm osteoblast 
differentiation on the Ti-Dex-BMP2 substrate (Fig. 4.4a). The results were 
compared with those from hFOBs (positive control) and untreated hMSCs 
(negative control) cultured on plastic.  Fig. 4.4b shows the relative levels of 
expression of the 3 genes in hMSCs, hFOBs and Ti-Dex-BMP2 cells, normalized 
to the expression level of GAPDH.  Other than Col I, hMSCs had no detectable 
levels of Runx2 and OCN.  Table 4.1 shows the primers used for the RT-PCR 




















































Fig. 4.4a & 4.4b.  RT-PCR of Runx2, Col I and OCN suggests that Ti-
Dex-BMP2 cells are undergoing osteoblast differentiation, unlike 
hFOBs (positive control), which are mature osteoblasts.  This is 
evident from the comparatively higher level of Runx2, indicating a 
higher transcription activity level of this gene, and the relatively lower 
levels of Col I and OCN, indicating that the Ti-Dex-BMP2 cells are not 
fully differentiated osteoblasts yet.  Conversely, untreated, hMSCs 
cultured in plastic culture flasks (negative control) do not differentiate 
and hence have no detectable level of bone-related markers except 


















    
RUNX2 
(NM_004348)  
Forward   tttgcactgggtcatgtgtt 





    
Collagen I 
(NM_000088) 
Forward   ccaaatctgtctccccagaa 









Forward   gtgcagagtccagcaaaggt 







    
GAPDH 
(NM_002046) 
Forward   gagtcaacggatttggtcgt 





    
    
 
 
Table 4.1.  Primers used for the reverse transcription-polymerase chain 
reaction of bone-related genes. 
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Alizarin Red staining 
 The Ti-CS-BMP2 cells were stained with Alizarin Red S to detect calcium 
deposits in the cells.  Fig. 4.5a shows the some of the positively-stained cells.  
Untreated hMSCs stained negative with Alizarin Red S, as shown in Fig. 4.5b. 
 
 





Fig. 4.5a & Fig. 4.5b.  Ti-Dex-BMP2 cells that stain positive for the 
presence of calcium deposits with Alizarin Red S indicate osteoblast 
differentiation (Fig. 4.5a), while untreated, cultured hMSCs do not 
differentiate and hence stain negative for Alizarin Red S (Fig. 4.5b).      
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Discussion          
 MSCs are a heterogenous mix of cells with different proliferation 
capacities [154].  Despite their varying differentiation potential, the default 
differentiation pathway is usually osteogenesis [155-159].  These cells have been 
reported to retain their undifferentiated phenotype and remain capable of 
osteogenic differentiation during ex vivo expansion through multiple passages 
[132].   Their surface marker expression profiles remain consistent, and their 
gene expression profiles do not change significantly during long-term expansion 
[132].       
 Initial attachment of hMSCs onto the surface of the titanium substrates is 
paramount for cell proliferation and osteoblast differentiation to take place in vivo.  
The present results show that upon cell attachment on all the titanium substrates 
except the Ti-Dex substrate, the hMSCs steadily proliferated until day 7, when 
proliferation was seen to slow down.  This suggests that the cells were 
undergoing differentiation, since differentiating cells are known to slow down in 
proliferation rate or even leave the cell cycle [125].  The BMP2 coating on the Ti-
Dex-BMP2 substrates appears to have enhanced initial cell attachment, probably 
by stimulating biological responses in the cells which come into contact with the 
substrates.  BMP2 is known to increase the expression of cytoskeletal proteins 
[160].  An increase in the expression of cytoskeletal proteins probably contributes 
to improved cell spreading and migration, thereby encouraging a strong and 
evenly distributed cell attachment over the substrate surface.   
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 Osteoblast differentiation possibly occurred on the Ti and Ti-Dex-BMP2 
substrates soon after cell attachment, as suggested by the results of the ALP 
activity assay on day 7 of culture (Fig. 3).  Others have used calcium phosphate-
coated, collagen-coated, or chondroitin sulphate-coated titanium to enhance the 
retention of BMP2 on the substrate surface [121, 122, 137].  BMP2 was 
covalently attached to dextran-grafted titanium substrates and achieved almost 
95% retention of the BMP2 on the substrate surface after 14 days.  Whereas 
physically adsorbed BMP2 may gradually detached and diffuse into the 
surrounding tissue fluids, covalently attached BMP2 can remain on the substrate 
for a sufficiently long period of time to support osteoblast differentiation.  Thus, 
localized BMP2 can possibly enhance osteoblast differentiation at the implant 
site since in clinical practice, osteoblast attachment and bone formation are 
known to occur on unmodified titanium implants.     
 Based on the ALP assay which showed that the Ti-Dex-BMP2 cells had 
the highest level of activity, the expression levels of three bone genetic markers 
in the cells on the Ti-Dex-BMP2 substrates were assessed.  RT-PCR was carried 
out to assess the expression levels of three key bone markers, Runx2, Col I and 
OCN.  Runx2 is the trasnscription gene of the osteoblast specific protein, 
osteocalcin.  Together, Runx2 and OCN are the key regulators of osteoblast 
differentiation and function [143-145].  Runx2 functions as a scaffold protein for 
nucleic acids and regulatory factors involved in skeletal gene expression.  
Osteocalcin is the major noncollagenous protein of bone matrix and thus serves 
as a convenient biomarker of osteoblast differentiation [146].  Interestingly, 
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serum OCN levels may indicate the point of severity of the disease at which a 
bone implant should be considered, as OCN  has been implicated in human 
osteoarthritis [146].  The major constituent in bone extracellular matrix, collagen 
I, mediates the transduction of extracellular signals into the cells through its 
interaction with the α2β1 integrin receptor on the cell membrane [147, 148].  
Disruption to this collagen-integrin interaction can thus inhibit osteoblast 
differentiation from bone marrow cells [148].  RT-PCR analysis shows that 
Runx2, Col I and OCN are expressed in the Ti-Dex-BMP2 cells, whereas only 
Col I is expressed in the untreated hMSCs.  The comparatively lower levels of 
Col I and OCN in the Ti-Dex-BMP2 cells as compared with those from the hFOBs 
suggests that the Ti-Dex-BMP2 cells are in the early stages of osteoblast 
differentiation (Fig. 4b).  This is further corroborated by the relatively higher level 
of the transcription factor, Runx2, indicating a higher bone related gene 
transcription activity level in Ti-Dex-BMP2 cells than in hFOBs.  Additionally, the 
hFOBs were assessed for the expression of endogenous BMP2, which is a key 
gene in bone cells, as BMP2 also serves to regulate the Runx2 gene.  Finally, 
the Ti-Dex-BMP2 cells were stained with Alizarin Red S to detect intracellular 
calcium deposits.  There could be a possibility that there exists in the hMSCs, a 
small population of cells that are already committed to the osteoblast lineage.  
However, the results show that by day 7, the cells attached onto the Ti-Dex-
BMP2 substrates did not continue to proliferate.  Furthermore, RT-PCR results 
from the untreated hMSCs do not reveal the expression of Runx2 and OCN.  
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Thus, the hMSCs differentiated into osteoblasts under the influence of the 
immoblilized BMP2 on the substrate.   
 
Conclusion    
Implant related bacterial infections and the lack of osseointegration 
between implant and host bone tissue can result in implant failure.  Hence, a 
favoured strategy to combat bacterial infections and to promote osseointegration 
would be to develop an implant surface that is anti-bacterial and 
osteoconductive.  In Chapter 3, it has been shown that the Ti-CS-BMP2 
substrate is able to support the differentiation of mesenchymal stem cells into 
osteoblasts.  In this chapter, work is done to study another method to surface 
modify the titanium substrate.  The titanium substrate is first surface modified by 
covalently grafting dextran onto the titanium surface.  Subsequently, BMP2 is 
covalently grafted onto the dextran coat.  While dextran-grafted titanium has 
been shown to resist bacteria adhesion, it does not favour human mesenchymal 
stem cell (hMSC) adhesion.  However, further modification with covalently 
grafted BMP2 on the dextran coat enhanced hMSC adhesion and proliferation.  
The attached hMSCs also underwent active differentiation into osteoblasts. This 
is evident from their relatively higher level of transcription activity of Runx2 and 
lower levels of collagen I and osteocalcin expressions, as compared with human 
osteoblasts (hFOB).  Osteoblast differentiation is confirmed by Alizarin Red 
staining, which revealed the presence of intracellular calcium deposits.   
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Although surface modification of titanium has been reported to enhance 
the attachment of BMP2 on the substrate surface, there are concerns that 
biomimetic coatings do not enhance bone formation [121, 122].  It is shown in 
this chapter that the method of covalently attaching BMP2 onto dextran-grafted 
titanium is an effective way to confer upon the substrate surface anti-bacterial 
and osteogenic properties.  The Ti-Dex-BMP2 substrate therefore has the 
potential to be used to fabricate anti-bacterial, osteoconductive bone implants.    
The work done in Chapters 3 and 4 has enabled a selection of one of the two 













Chapter 5   
Improvement to the Ti-CS-BMP2 substrate   
Glutaraldehyde crosslinking of BMP2 to chitosan-grafted titanium 

















Introduction          
 In chapter 4, the Ti-Dex-BMP2 substrate is found to be osteogenic.  
However, the substrate requires a tedious preparation process as compared with 
the Ti-CS-BMP2 substrate described in chapter 3.  Chitosan is proposed to alter 
the surface charge on the bacterial cell wall, leading to bacterial cell lysis and 
leakage of cellular contents.  On the other hand, dextran only prevents initial 
bacterial cell adhesion.  Hence, on the basis of the anti-bacterial mechanism and 
the complexity of the substrate fabrication procedure, the Ti-CS-BMP2 substrate 
is chosen for further studies on a method to enhance the firmer attachment of 
BMP2 on the Ti-CS surface, and the subsequent work in chapter 6.   
Physical adsorption of BMP2 onto the Ti-CS substrate surface is a 
relatively simple and convenient method.  However, adsorption is probably 
mediated by electrostatic forces which results in a substrate with a low surface 
density of BMP2.  Adsorbed BMP2 is also progressively lost from the substrate 
surface.  Loss of BMP2 molecules from the substrate surface could potentially 
give rise to implicating factors if the substrate is to be used for other studies.  
Thus, an improved method to firmly attach BMP2 onto the Ti-CS surface is 
required.  In the present study, glutaraldehyde, a common crosslinker used to 
crosslink proteins, is used to crosslink BMP2 to the Ti-CS surface.  
Glutaraldehyde crosslinking effectively anchors a high density of BMP2 onto the 
chitosan layer of the Ti-CS substrate surface.  Crosslinked BMP2 molecules are 
also more firmly attached than those which are physically adsorbed.  
Consequently, a relatively consistent and high percentage of attached BMP2 
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remains available for osteogenic differentiation for a substantially longer period of 
time.  Implicating factors due to substrate variability resulting from the loss of 










Materials and methods 
 Materials and methods specific to this chapter are described below.  All 
the other materials and methods used in this chapter are described in Chapter 2 
(General materials and methods). 
In order to avoid implicating factors due to patient variability, patient bone 
marrow-derived mesenchymal stem cells and patient bone chip-derived 
osteoblasts were not used in the present study.  Instead, appropriately 
characterized human mesenchymal stem cells (hMSC) and human osteoblasts 
(hFOB) were purchased from Lonza, USA, a commercial source and used for all 
the experiments in this study.   
 
Preparation of the Ti-CS-BMP2(gluta) substrates    
Ti foils of 0.52-mm thickness were cut to a size of 1 cm X 1 cm, and 
cleaned with sandpaper, followed by sonication sequentially in Knoll’s reagent 
(4.0% HF, 7.2% HNO3, 88.8% water), dichloromethane, acetone and water.  
After surface passivation in 40% HNO3, dopamine was anchored to the surface 
of the Ti substrates by immersion in a 1 mg / ml solution of dopamine at room 
temperature in the dark overnight, as described elsewhere [123].  Unbound 
dopamine was washed off with copious PBS and the substrates were air dried in 
a sterile environment.  Subsequently, the substrates were immersed in a stirred 
3% glutaraldehyde solution at room temperature overnight.  Glutaraldehyde 
serves as a cross-linker, providing the reactive aldehyde groups for covalently 
bonding dopamine and CS.  Unbound glutaraldehye was removed by rinsing the 
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substrates in water.  CS was dissolved in a 0.1% dilute acetic acid to a 
concentration of 5 mg / ml.  The glutaraldehyde-treated substrates were then 
immersed in the CS solution.  Imine bonds are formed between the aldehyde 
groups on the Ti surface and the primary amino groups at the C-2 position of CS.  
The resulting substrates were then washed with water and dried under vacuum.  
The Ti-CS substrates were subsequently immersed in a 3% glutaraldehyde 
solution (pH = 8.0) and left at room temperature overnight.  After washing to 
remove unbound glutaraldehyde, the substrates were individually coated with 
BMP2 (from a 50 µg / ml BMP2 solution) and left at room temperature overnight.    
Following which, the substrates were rinsed with sterile PBS to remove unbound 
BMP2 and left to air dry in a sterile environment before use.  The substrates are 
denoted Ti-CS-BMP2(gluta) in all subsequent discussions.  All the biological 
assays were done in duplicates, and each assay was done twice. 
 After the preparation of the Ti-CS-BMP2(gluta) substrates, the following 
were subsequently done, and the procedures are described in chapter 2: 
Stability and surface density of BMP2 on Ti-CS-BMP2(gluta) substrates 
 Culture of hMSCs 
 Culture of hFOBs 
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Differentiation of hMSCs into osteoblasts on the Ti-CS-BMP2(gluta) substrate 
The substrates were placed into a 24-well plate and seeded with hMSCs 
at a density of 10 000 cells / cm2.  Two ml of osteogenic medium comprising 
normal hMSC culture medium supplemented with 10 nM dexamethasone, 7 mM 
β-glycerophosphate and 0.2 mM ascorbic acid were added to each well.  Half of 
the medium was removed and replaced with fresh medium after every 2 days.  
The cells were allowed to differentiate for 7 days before being used for the ALP 
assay, to ascertain if the Ti-CS-BMP2(gluta) cells have differentiated into 
osteoblasts.  The ALP assay procedure is described in chapter 2.  As a control, 
hMSCs were also cultured on Ti-CS-BMP2(gluta) substrates with the BMP2 heat-
denatured at 80oC for 10 minutes in an oven.  hFOBs and hMSCs, grown on 
normal plastic culture dish, were used as the positive control and the negative 










Results    
Stability and surface density of BMP2 on Ti-CS-BMP2(gluta) substrate 
 In this chapter, an improved technique of attaching BMP2 onto the Ti-CS 
substrate is described.  BMP2 is crosslinked to the grafted chitosan layer on the 
Ti-CS substrate using glutaraldehyde.  The results show that about 46% of the 
BMP2 used to coat each substrate, or 23 µg, is stably attached onto the Ti-CS 
surface.  By day 9, about 95% of the originally attached BMP2 remains attached 





















































Fig. 5.1.  BMP2 is crosslinked to the Ti-CS substrate surface using 
glutaraldehyde.  Approximately 46% of the BMP2 used to coat the surface is 
firmly attached.  By day 9, about 95% of the attached BMP2 remains stably 
adhered to the substrate surface.   
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Alkaline phosphatase assay 
 The results show that the hMSCs growing on the Ti-CS-BMP2(gluta) 












































 Fig. 5.2.  By day 7, hMSC grown on the Ti-CS-BMP2(gluta) substrate had 
begun differentiating into osteoblasts, as shown by the ALP assay.   hMSCs 
grown on the Ti-CS-BMP2(gluta) substrates with heat-denatured BMP2 
(denoted by Ti-CS-BMP2(gluta)#) did not differentiate into osteoblasts.  
Untreated hMSCs cultured on normal plastic culture dish were used as a 
negative control while cells from a human foetal osteoblast (hFOB) cell line 
were used as a positive control.  Statistical significance was accepted at p < 
0.05.  Error bars represent the standard deviation of each group.  
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Discussion             
 In the preliminary study in Chapter 3, BMP2 was allowed to adsorb onto 
the Ti-CS substrate.  Adsorption of BMP2 is probably mediated by electrostatic 
forces.  Hence, the surface density of BMP2 on the substrate surface is low.  
Weak binding forces probably also contribute to the gradual loss of BMP2 from 
the substrate.  The gradual loss of BMP2 may present other implicating variables 
if the substrate is used to study the response of differentiating osteoblasts 
subjected to LPS treatment (Chapter 6).  Therefore, an improved method is 
devised to attach BMP2 onto the Ti-CS substrate.  A 3% aqueous solution of 
glutaraldehyde at pH 8.0 is used to crosslink BMP2 to the chitosan layer on the 
Ti-CS surface to achieve a stable, high surface density coating of BMP2.  This 
improved substrate is then used for the study in Chapter 6.  Studies of collagen 
crosslinking with aldehydes of various carbon lengths have established that the 
highest reactivity occurs at five carbons.  Hence, glutaraldehyde, being a 5-
carbon dialdehyde, is an effective crosslinking agent.  It is more efficient than 
other aldehydes in generating thermally and chemically stable crosslinks [161].  
This is due to the formation of intra- and inter-molecular crosslinks which results 
in a more rigid protein molecule that is resistant to conformational changes.  
However, the reaction conditions must be carefully chosen so that inter-
molecular crosslinks between the BMP2 molecules are favoured.  During the 
crosslinking process, covalent bonds are formed.  These bonds are stable in the 
presence of substrates or solutions of high ionic strength.  Crosslinked protein 
molecules remain stable over a wide range of pH and temperature, without 
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dissolution or deterioriation.  The fragile proteins after being crosslinked are more 
sturdy and robust, and are thus less susceptible to damage during physical 
handling.  Yet, their crystal structure remains permeable to dissolved solutes.  
The process of crosslinking thus confers mechanical advantages to proteins, 
which otherwise are easily damaged and lose their biological activity. 
 
Glutaraldehyde exists in multi-molecular forms    
Various molecular forms of glutaraldehyde in aqueous solution can exist 
[162].  Hence, commercially available glutaraldehyde consists of a mixture of 
multi-molecular forms.  Under acidic or neutral conditions, glutaraldehyde can 
exist as a free aldehyde monomer (Structure I), as a cyclic hemiacetal monomer 
(Structure II), or as cyclic hemiacetal oligomers (Structure III) (Fig. 5.4) [163].  In 
alkaline solutions, as in the present study, where the pH value of the 
glutaraldehyde solution is 8.0, glutaraldehyde forms polymers (Structure IV) (Fig. 
5.4) [164].  Thus, the effectiveness of glutaraldehyde immobilization and the 
reaction mechanism involved is possibly a consequence of the existence of the 
glutaraldehyde structures depending on the solution conditions.   
 



















































Fig. 5.3.  Under acidic or neutral conditions, glutaraldehyde can exist as a 
free aldehyde monomer (Structure I), as a cyclic hemiacetal monomer 
(Structure II), or as cyclic hemiacetal oligomers (Structure III).  In alkaline 
solutions, glutaraldehyde forms polymers (Structure IV).  (Adapted from Rini 
et. al.  J Clin Oncol 23 (2005), pp. 1028-1043 and Barrère et. al. Materials 
Science and Engineering: R: Reports 59 (2008), pp. 38-71.) 
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The reactivity of glutaraldehyde toward proteins       
The chemical behaviour of glutaraldehyde in aqueous solutions has been 
intensively studied [162].  In acidic conditions, the kinetics of glutaraldehyde 
crosslinking is slower than that in alkaline conditions [164].  For example, the 
mildly acidic pH value of 4.5 is considered to be unfavourable for glutaraldehyde 
crosslinking as the amino groups of the protein are likely to be protonated [165].  
Accumulated data show that in alkaline solutions, glutaraldehyde undergoes 
polymerization, resulting in a mixture of polymeric chains consisting of 
CH=C(CHO) groups [166].  it is possible that during crosslinking of proteins, 
glutaraldehyde or its polymerization products may react with several functional 
groups like amine, thiol, phenol and imidazole [167].  These amino acid side-
chains are reactive because they are nucleophiles.  The crosslinking is attributed 
mainly to the reactions with the ε-amino groups of the lysine residues [168].  
When crosslinking is carried out under alkaline conditions, the polymeric 
glutaraldehyde affects crosslinking by way of two reactions, namely, Schiff base 
formation with an amino group from one protein molecule and a C-N bond 
formation by Michael addition to the β-carbon of its adjunct double bond by 
another amino group from a neighbouring protein molecule (Fig. 5.4a & Fig. 5.4b 
) [164].  Thus, the probable mechanism in the crosslinking of BMP2 to the 
chitosan layer on the Ti-CS substrate involves Schiff base formation between the 
glutaraldehyde polymer and the amino groups of BMP2 and chitosan.  This is 
then followed by the formation of a C-N bond to the respective β-carbon of the 
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adjunct double bond in the glutaraldehyde polymer by another amino group from 



















































Fig. 5.4a and Fig. 5.4b.  The schematic in (a) illustrates the crosslinking of 
lysine residues from two protein molecules by monomeric glutaraldehyde.  
The schematic in (b) illustrates the suggested end product obtained from the 
reaction of polymeric glutaraldehyde with lysine residues of the crosslinked 
proteins under alkaline conditions.   
 128 
Efficiency of glutaraldehyde-mediated crosslinking   
       The stability and surface density of BMP2 adsorbed onto the Ti-CS 
substrate has been shown to be approximately 1% of the BMP2 from the coating 
solution as described in Chapter 3.   Approximately 2% per day of the stably 
adsorbed BMP2 is released into solution after the initial spike of loosely bound 
BMP2 detachment from the substrate surface.  In this study, glutaraldehyde 
crosslinking of BMP2 to chitosan enables a relatively higher density of BMP2 to 
be attached on the Ti-CS surface.  The covalently bound BMP2 molecules are 
also more stably attached.  By day 9, about 95% of the originally attached BMP2 
remain adhered to the substrate surface.   
 
Glutaraldehyde crosslinking does not compromise the biological activity of BMP2   
 Covalent crosslinking of BMP2 using glutaraldehyde does not compromise 
the biological activity of this growth factor.  The hMSCs grown on the substrate 
differentiated into osteoblasts by day 7, as confirmed by the ALP activity, as well 








Conclusion     
 The adsorption of BMP2 onto the chitosan-grafted titanium (Ti-CS) 
substrate surface is possibly mediated by electrostatic forces.  Although a simple 
and convenient method to use, physical adsorption results in a substrate with a 
low surface density of BMP2.  The attachment of BMP2 molecules mediated by 
electrostatic forces is relatively weak compared with covalent linkage, resulting in 
the progressive loss of BMP2 from the substrate surface.  In the present study, 
glutaraldehyde is used to crosslink BMP2 to the Ti-CS substrate surface.  
Crosslinking enables a relatively higher surface density of BMP2 to be grafted on 
the substrate surface, as compared with using the adsorption method.  The 
BMP2 molecules are also more firmly attached.  The results show that 
glutaraldehyde crosslinking does not adversely affect the ability of BMP2 to 
induce the differentiation of hMSCs into osteoblasts. Thus, glutaraldehyde 
crosslinking is an effective method to achieve a firm and dense coating of 








Chapter 6   
Simulation of implant bacterial infection 
Effect of Sphingosine-1-phosphate on LPS-treated human mesenchymal 
stem cell-derived osteoblasts cultured on bone morphogenetic protein-2-

















Bone implant failures are mainly due to bacterial infection at the implant 
site or failure of osseointegration of bone tissue with the implant surface.  A 
logical approach to circumvent these two problems would be to surface modify 
the implant material to render it osteogenic and anti-bacterial.  Despite efforts to 
prevent initial bacteria adhesion on an implant surface, bacteria from the patient’s 
own skin or mucosa may enter the wound site during surgical insertion of a bone 
implant.  The attached bacteria then secrete a thick extracellular matrix, leading 
to the formation of a biofilm.  The thick extracellular matrix delays the penetration 
of antimicrobial agents, making the bacteria very resistant to host defence 
mechanisms and antibiotics.  Implant-related infection can lead to osteomyelitis, 
localized bone destruction and eventually implant failure.  Effective treatment of 
implant-related infections is hindered by the evolution of antibiotic-resistant 
bacteria.  Thus, besides the development of implant surfaces that 
inhibitsbacterial adhesion, there is also a need to seek an effective way to down-
modulate the inflammatory response should an infection occur.  This may 
enhance the chances of a successful implant while treatment for the infection is 
continued.  Besides endotoxins from bacterial infections, trace amounts of 
endotoxins like LPS have been detected on commercially pure implant surfaces 
[169].  In this chapter, a study is done to investigate the effect of sphingosine-1-
phosphate (S1P) on LPS-treated differentiating osteoblasts grown on the Ti-CS-
BMP2(gluta) substrate.  This improved substrate (described in Chapter 5) is used 
to simulate an opportunistic bacterial infection that occurs despite the chemical 
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treatment done to render the substrate anti-bacterial.  Glutaraldehyde-
crosslinking of BMP2 to the chitosan-coated surface of the substrate will ensure 
that a sufficient amount of BMP2 is available for osteoblast differentiation.  
Together, these two features of the improved substrate make it a suitable 
substrate for examining the effects of LPS on the differentiating osteoblasts.  A 
prior discussion on the relevant aspects of the osteoimmunology in this study to 
enable a better appreciation of the potential therapeutic benefit of S1P to 
differentiating osteoblasts exposed to LPS has been presented in chapter 1, 
wherein the interaction of the bacterial endotoxin LPS with the CD14/TLR4/MD2 
receptor complex, TNFα and S1P have been discussed.  One aim of the present 
study is to find out if S1P can rapidly downregulate the expression of TLR4 and 
TNFα after prolonged LPS exposure, and thereby induce LPS tolerance in 
differentiating osteoblasts.  Another aim of the present study is find out whether 
S1P can upregulate the expression of the bone-related genes, Runx2 and OCN, 
thereby maintaining the bone cell characteristics of developing osteoblasts during 





Materials and methods 
 Materials and methods specific to this chapter are described below.  All 
the other materials and methods used in this chapter are described in Chapter 2 
(General materials and methods) and Chapter 5 (Glutaraldehyde crosslinking of 
BMP2 to chitosan-grafted titanium substrate). 
In order to avoid implicating factors due to patient variability, patient bone 
marrow-derived mesenchymal stem cells and patient bone chip-derived 
osteoblasts were not used in this study.  Instead, appropriately characterized 
human mesenchymal stem cells (hMSC) and human osteoblasts (hFOB) were 
purchased from Lonza, USA, a commercial source and used for all the 
experiments in this study.   
 
Preparation of the Ti-CS-BMP2(gluta) substrate     
The preparation of the Ti-CS-BMP2(gluta) substrate is described in 
chapter 5. 
 After the preparation of the Ti-CS-BMP2(gluta) substrates, the following 
were subsequently done, and the procedures are described in chapter 2: 
Stability and surface density of BMP2 on the Ti-CS-BMP2(gluta) substrate   
 Culture of hMSCs 
Culture of hFOBs  
 
Differentiation of hMSCs into osteoblasts on the Ti-CS-BMP2(gluta) substrate 
The procedure is described in chapter 5. 
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Treatment with LPS and LPS/S1P 
After 7 days of differentiation in osteogenic medium, the hMSC-derived 
osteoblasts growing on the Ti-CS-BMP2(gluta) substrates were subjected to LPS 
treatment or LPS/S1P treatment.  Treatment was done for 1 day to simulate a 
short LPS exposure and 7 days to simulate a prolonged LPS exposure.   
 
 LPS treatment 
 LPS was added to the osteogenic medium to a concentration of 10 
µg / ml.  Half of the medium was removed and replaced with similarly LPS-
supplemented medium every 2 days.   
 
LPS/S1P treatment 
LPS and S1P were added to the osteogenic medium to a 
concentration of 10 µg / ml and 1 µg / ml respectively.  Half of the medium 
was removed and replaced with similarly LPS/S1P-supplemented medium 
every 2 days.   
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Reverse transcription-polymerase chain reaction 
 RNA was extracted from cells on day 1 (short LPS exposure) and day 7 
(prolonged LPS exposure) of culture using the NucleoSpin®  RNA / Protein 
isolation kit (Macherey-Nagel, GmbH, Germany) according to the manufacturer’s 
instructions.  Each sample of RNA was diluted 50X with DEPC 
(diethypyrocarbonate) water and the RNA concentration was measured using the 
NanoDrop ND1000 spectrophotometer.  1 µg of each sample of total RNA was 
used for the RT-PCR reaction.  Reverse transcription of mRNA to cDNA and 
subsequent cDNA amplification was done using the TITANIUM™ One-step RT-
PCR Kit (Clontech Laboratories, Inc., US), through one cycle at 50oC for 1h and 
94oC for 5 minutes.  This was followed by 32 cycles at 94oC for 30 seconds, 60oC 
for 30 seconds and 68oC for 1 minute, with a final extension at 68oC for 2 
minutes.  The expression of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was used to check RNA integrity.  The amplified products were 
subjected to electrophoresis in a 2% agarose gel and stained with ethidium 
bromide (Sigma-Aldrich, Singapore).  Densitometry was done to quantify the 
relative levels of the bone-related genes, Runx2, OCN and RANKL, the LPS 
receptor, TLR4, and the inflammatory cytokine, TNFα, all normalized to the 
respective levels of GADPH.  Primers used for the cDNA amplification and the 
annealing temperatures are listed in Table 6.11.  RT-PCR of the gene expression 




Results     
RT-PCR 
RT-PCR was carried out to assess the relative expression levels of the 
relevant genes, normalized to the respective GAPDH levels, after treatment with 
LPS or with LPS/S1P.   
 
 Expression of TLR4 
 LPS treatment - TLR4 levels on D1 and D7 
This comparison is done to determine if the osteoblasts (OB) develop LPS 
tolerance upon prolonged LPS exposure.  Table 6.1 and Fig. 6.1 show 
that the TLR4 level on D7 is significantly lower (p < 0.05) than that on D1 
(denoted by # on Fig. 6.1).  This suggests that the OBs have probably 
developed LPS tolerance.   
 
 LPS/S1P treatment – TLR4 levels on D1 
This comparison of the TLR4 levels on D1 (short LPS exposure) is to 
determine if S1P has any effect on the LPS-treated OBs.  Table 6.2 and 
Fig. 6.1 show that LPS/S1P-treated OBs have a significantly lower (p < 
0.05) TLR4 level than LPS-treated cells (denoted by * on Fig. 6.1).  This 
















Table 6.2.  Comparision of TLR4 expression between LPS and 










 D1 D7 








p value of difference between D1 and D7: <0.05 
 LPS LPS/S1P 












 Fig. 6.1.  The expression of the LPS receptor, TLR4, is significantly 
downregulated (n = 3) (P < 0.05) by day 7 during prolonged LPS 
treatment (denoted by **), indicating that the hMSC-derived OBs could 
have developed LPS tolerance.  However, TLR4 expression in the OBs 
subjected to LPS/S1P treatment (denoted by *) is significantly 
downregulated (n = 3) (p < 0.05) by day 1.  Hence, S1P-mediated 
down-modulation of TLR4 expression suggests that S1P is able to 
confer protection against LPS damage in OBs by rapidly inducing LPS 
tolerance.  Error bars represent the standard deviation of each group.     
** 
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 Expression of TNFα   
 LPS treatment - TNFα levels on D1 and D7 
This comparison is done to determine the effect of prolonged LPS 
treatment on TNFα expression in the OBs. Table 6.3 and Fig. 6.2 show 
that the TNFα level on D7 is significantly lower (p < 0.05) than that on D1  
(denoted by** on Fig. 6.2).  This suggests that the OBs have probably 
developed LPS tolerance.   
 LPS/S1P treatment – TNFα levels on D1 
This comparison of the TNFα levels on D1 (short LPS exposure) is to 
determine if S1P has any effect on the expression of this inflammatory 
cytokine following LPS treatment of the OBs.  Table 6.4 and Fig. 6.2 show 
that LPS/S1P-treated OBs have a significantly lower (p < 0.05) TNFα level 
than LPS-treated cells (denoted by * on Fig. 6.2).  The results strongly 
suggest that S1P is able to protect the OBs against LPS-induced damage 



















Table 6.4.  Comparision of TNFα expression between LPS and 









 D1 D7 








p value of difference between D1 and D7: <0.05 
 LPS LPS/S1P 















Fig. 6.2.  The inflammatory cytokine TNFα is downregulated by about 
12% by day 7 (n = 3) (p < 0.05) indicating that the OBs probably has 
developed LPS tolerance (denoted by **).  However, LPS/S1P 
treatment mediates the down-modulation of TNFα by about 44% by day 
1 (n = 3) (denoted by *).  This suggests that S1P may protect the OBs 
against LPS-induced damage by mediating the rapid downregulation of 
TNFα expression.  Error bars represent the standard deviation of each 
group.     
** 
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 Expression of Runx2 
 LPS treatment – Runx2 levels on D1 and D7 
This comparison is done to determine the effect of prolonged LPS 
exposure on the Runx2 expression level of the OBs.  Table 6.5 and Fig. 
6.3 show that the Runx2 level on D7 is significantly lower (p < 0.05) than 
that on D1 (denoted by * on Fig. 6.3).  This suggests that prolonged LPS 
exposure could have a detrimental effect on the bone cell characteristics 
of the OBs. 
 
 LPS/S1P treatment – Runx2 levels on D7 
Prolonged LPS has been shown above to have an undesirable effect on 
Runx2 expression.  This comparison of the Runx2 levels on D7 is to 
determine if S1P has any effect on the expression of this transcription 
factor in the OBs following prolonged LPS treatment.  Table 6.6 and Fig. 
6.3 show that LPS/S1P-treated OBs have a significantly higher Runx2 
expression level (p < 0.05) than LPS-treated cells (denoted by ** on Fig. 
6.3).  This suggests that S1P is able to restore Runx2 expression in the 



















Table 6.6.  Comparision of Runx2 expression between LPS and 
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P value of difference between D1 and D7: < 0.05 
 LPS LPS/S1P 













 Fig. 6.3.  Runx2 expression is downregulated following prolonged LPS 
treatment (n = 3) (denoted by *).  However, in the LPS/S1P treatment, 
Runx2 expression level is significantly higher than that in the LPS 
treatment (n = 3) (p < 0.05) (denoted by **).  S1P is probably able to 
maintain OB differentiation despite prolonged LPS exposure.  Untreated 
hMSC are used as the negative control (n = 3) and hFOB cells are used 
as the positive control (n = 3).   Error bars represent the standard 




 Expression of OCN 
 LPS treatment – OCN levels on D1 and D7 
This comparison is done to determine the effect of prolonged LPS 
exposure on the OCN expression level of the OBs.  Table 6.7 and Fig. 6.4 
show that the Runx2 level on D7 is significantly lower (p < 0.05) than that 
on D1 (denoted by * on Fig. 6.4).  The results again suggest that 
prolonged LPS exposure could have a detrimental effect on the bone cell 
characteristics of the OBs. 
 
 LPS/S1P treatment – OCN levels on D7 
Prolonged LPS has been shown above to have an undesirable effect on 
OCN expression.  This comparison of the OCN levels on D7 is to 
determine if S1P has any effect on the expression of this bone-specific 
protein in the OBs following prolonged LPS treatment.  Table 6.8 and Fig. 
6.4 show that LPS/S1P-treated OBs have a significantly higher OCN 
expression level (p < 0.05) than LPS-treated cells (denoted by ** on Fig. 
6.4).  The results thus again suggest that S1P is able to restore OCN 
expression in the OBs and thus maintain their bone cell characteristics 















           
 
 
Table 6.8.  Comparision of OCN expression between LPS and 
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P value of difference between D1 and D7: < 0.05 
 LPS LPS/S1P 
















Fig. 6.4.  Prolonged LPS exposure downregulates OCN gene 
expression (n = 3) (denoted by *).  However, LPS/S1P treatment 
appears to restore the OCN gene expression (n = 3) (p < 0.05) 
(denoted by **).  S1P is probably able to maintain OB differentiation 
despite prolonged LPS exposure.  Untreated hMSCs are used as the 
negative control (n = 3) and hFOB cells are used as the positive control 
(n = 3).  Error bars represent the standard deviation of each group.       
** 
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 Expression of RANKL 
 LPS treatment – RANKL levels on D1 and D7 
This comparison is done to determine the effect of prolonged LPS 
treatment on RANKL expression in the OBs. Table 6.9 and Fig. 6.5 show 
that the RANKL level on D7 is significantly higher (p < 0.05) than that on 
D1 (denoted by * on Fig. 6.5).   
 
 LPS/S1P treatment – RANKL levels on D7 
Prolonged LPS exposure has been shown above to upregulate the 
expression of RANKL.  This comparison of the RANKL levels on D7 is to 
determine if S1P has any effect on the expression of RANKL following 
prolonged LPS treatment of the OBs.  Table 6.10 and Fig. 6.5 show that 
LPS/S1P-treated OBs have a significantly higher (p < 0.05) RANKL level 
than LPS-treated cells (denoted by ** on Fig. 6.5).  This indicates that S1P 
may enhance the effect of LPS in upregulating the expression of RANKL. 

















           
 
 
Table 6.10.  Comparision of RANKL expression between LPS and 
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P value of difference between D1 and D7: <0.05 
 LPS LPS/S1P 














    
               
Fig. 6.5.  Prolonged LPS treatment upregulates RANKL expression in 
the differentiating OBs (n = 3) (p < 0.05) (denoted by *).  LPS/S1P 
treatment induces a significantly higher level of RANKL expression than 
with LPS alone (n = 3) (p < 0.05) (denoted by **).  S1P probably 
enhances the effect of LPS in upregulating RANKL gene expression.  
Untreated hMSCs are used as the negative control (n = 3) and hFOB 
cells are used as the positive control (n = 3).  Error bars represent the 
standard deviation of each group.    
** 
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   Fig. 6.6a.  Gene expression level of TLR4. 
 
 



























Effect of S1P on LPS-treated, hMSC-derived OBs differentiating on Ti-CS-
BMP2(gluta) substrates     
In murine OBs, the phenomena of LPS-induced tolerance has been 
observed [170].  LPS activates NFκB through TLR4 signaling to induce cytokine 
production and increased bactericidal activities.  Chronically infected human 
osteocytes have also been found to express anti-microbial peptides [171].  Thus, 
LPS-induced tolerance is believed to be a mechanism to protect the host from 
hyperactivation of the innate immunity system.  In macrophages, LPS-tolerance 
results in the downregulation of the receptor, TLR4 [172].  Similarly, in hMSC-
derived osteoprogenitors, prolonged exposure to LPS downregulated the gene 
expression of TLR4 [173].  This is believed to be an adaptive response of OBs to 
an environment that is rich in microbial flora.  The gene expression of the TLR4 
receptor in differentiating OBs growing on Ti-CS-BMP2(gluta) substrates is 
downregulated by about 21% during prolonged LPS treatment (day 7), as shown 
in Fig. 6.1.  This indicates that the OBs similarly develop LPS tolerance after 
prolonged LPS exposure.  However, LPS/S1P treatment induced the 
downregulation of TLR4 by about 17% by day 1, suggesting that S1P can 
probably induce LPS tolerance in differentiating OBs rapidly, and maintain the 
protection throughout the duration of LPS exposure (Fig. 6.2). The level of the 
inflammatory cytokine TNFα is correspondingly downregulated by day 7 of LPS 
exposure (Fig. 6.3).  This suggests that hMSC-derived OBs may possess the 
ability to resist bacterial endotoxins like LPS.  However, LPS/S1P treatment 
 156 
reduces TNFα levels by 44% by day 1.  This strongly suggests that S1P is able 
to rapidly induce LPS tolerance in the differentiating OBs.  Taking into 
consideration the results in the present study and evidence from the work of 
others, S1P may have an anti-inflammatory effect on OBs which are 
differentiating on Ti-CS-BMP2(gluta) substrates and are exposed to LPS.   
 LPS exposure has been shown to downregulate the expression of Runx2 
in OBs [174].  Differentiating OBs in the present study behave similarly following 
LPS treatment (Fig. 6.5).  However, in the current study, the expression level of 
Runx2 is upregulated with S1P treatment despite prolonged LPS exposure.  
Similarly, OCN expression is reduced upon LPS exposure but with S1P 
treatment, the OCN expression level is upregulated even after prolonged LPS 
exposure (Fig. 6.6).  Thus, the results suggest that, by gradual or partial 
restoration of the expression of bone genes in the differentiating OBs, S1P helps 
to maintain their bone cell characteristics. 
 RANKL is a member of the TNF superfamily and shares much homology 
with TNFα [175].  Interaction of RANKL with its receptor, RANK, on osteoclast 
precursors stimulates the differentiation of osteoclasts and increase peri-implant 
bone resorption [176].  In inflammatory osteolysis, TNFα increases the 
expression of RANKL [175].  LPS treatment of differentiating OBs growing on the 
Ti-CS-BMP2(gluta) substrates similarly induces the increased level of RANKL 
expression as shown in Fig. 6.9.  Unfortunately, S1P also induces RANKL 
upregulation [98].   S1P treatment of the day 7 differentiating OBs exposed to 
LPS also showed an increase in RANKL level as shown in Fig. 6.10.  However, 
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increased RANKL expression may not be a clinically serious complication.   
RANKL levels can be managed by the administration of a monoclonal antibody 
against RANKL [177].    One such antibody is Denosumab, is a neutralizing fully 
human IgG2 antibody that targets specifically human RANKL to bring about a 



















Conclusion    
 Bone implant failures are mainly caused by poor osseointegration 
between implant and bone tissue, and by bacterial infection.  Despite efforts to 
minimize chances of initial bacterial adhesion on an implant surface, implant-
related infections do occasionally occur.  A bacterial infection can result in 
osteomyelitis and localized bone destruction, eventually leading to implant 
failure.  Besides the development of antibacterial implant surfaces, there is also a 
need to seek an effective way to down-modulate an inflammatory response 
should an implant-related infection occur.  In the present study, it is found that 
sphingosine-1-phosphate (S1P) rapidly downregulates osteoblast expression of 
TLR4 and TNFα, following LPS exposure.  This suggests that S1P is able to 
induce LPS tolerance in differentiating osteoblasts.  Thus, S1P is likely to play an 
anti-inflammatory role in differentiating Ti-CS-BMP2(gluta) OBs exposed to LPS, 
by downregulating the gene expression of TLR4 and TNFα.  The lower 
expression level of TLR4 probably reduces the sensitivity of the OBs to LPS, and 
consequently also reduces the expression level of TNFα.  During prolonged LPS 
exposure, S1P treatment also upregulates the expression of Runx2 and 
osteocalcin.  Hence, S1P possibly helps to maintain the integrity of the OBs in an 
LPS environment.  The findings from the present study indicate that S1P through 
its dual beneficial effect on osteoblasts exposed to LPS may be of potential 
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Introduction     
Biodegradable polymers play an important role in providing a temporary 
support for cell growth and differentiation.  Ideally, biodegradable polymers must 
possess the mechanical properties to suit the application and maintain the in vivo 
ambient environment.  They must also degrade into products that are harmless 
to the cells and tissues in the body after a suitable length of time.  Poly lactic-co-
glycolic acid (PLGA) is one such polymer which has been used to make sutures 
and other implantable structures, as well as 3-dimensional scaffolds as a support 
for tissue engineering [179].   In order to enhance initial cell attachment and cell 
differentiation on PLGA scaffolds, it is usually necessary to functionalize the 
scaffold surface with bioactive molecules [180, 181].  The adjustable degradation 
rate of PLGA presents an attractive option to make PLGA-based controlled 
release delivery devices.  PLGA can be grafted with bioactive molecules, to be 
released gradually to support cell differentiation.  Unfortunately, the 
functionalization of PLGA usually requires extensive chemical modification.  
Chemical surface modification of PLGA can compromise its mechanical strength 
[182].  Similarly, chemical modification of bioactive molecules may adversely 
alter their ability to bind onto their respective cell surface receptors, and thus 
decrease their biological activity [181].  Thus, a method of anchoring bioactive 
molecules in their native form to a substrate, which can also control the release 
of the molecules into solution, would be favoured.  In the present study, work was 
carried out to investigate the coating of an angiogenic factor, vascular endothelial 
growth factor (VEGF), on unmodified PLGA suture substrates to support the 
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differentiation of human mesenchymal stem cells (hMSCs) into endothelial cells 
















Materials and methods 
 Materials and methods specific to this chapter are described below.  All 
the other materials and methods used in this chapter are described in Chapter 2 
(General materials and methods). 
 In order to avoid implicating factors due to patient variability, patient bone 
marrow-derived mesenchymal stem cells were not used in this study.  Instead, 
appropriately characterized human mesenchymal stem cells (hMSC) were 
purchased from Lonza, USA, a commercial source and used in all the 
experiments in the present study.   
   
Materials  
Ethicon Coated VICRYL (polyglactin 910) (W9321) PLGA sutures with 
a glycolic to lactic acid ratio of 90:10 were purchased from Johnson & Johnson 
International.  Gelatin was purchased from Sigma-Aldrich Chemical Co. 
(Singapore).  Recombinant human VEGF was obtained from R&D Systems (US).  
The degradation of PLGA in solution was assessed by measuring the pH of the 
solution using a inoLab pH meter.  PE-conjugated CD133 antibody was 
purchased from eBioscience (San Diego, US).  FITC-conjugated polyclonal goat 
anti-mouse IgG antibody was purchased from AbD Serotec (UK).  Flk1-PE was 
purchased from R&D Systems (US).  Unconjugated monoclonal mouse anti-
human von Willebrand Factor (vWF) antibody was obtained from Abcam (UK).  
Unconjugated mouse-anti-human Tie2 antibody was purchased from Santa Cruz 
(US).    The intensity and stability of VEGF coated onto the suture substrate 
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surface were assessed using a human VEGF ELISA kit purchased from Bender 
MedSystems (Austria).  BD Matrigel Basement Membrane Matrix was obtained 
from BD Biosciences (US).   
 
Preparation of the PLGA-VEGF substrates 
The PLGA-VEGF substrates were prepared by stitching sutures onto a 
square grid 1 cm X 1 cm marked on the base of a plastic weighing boat, to form a 
suture mat on plastic base.  The suture substrates were sterilised by soaking in 
70% ethanol for 1 h, rinsed with copious amounts of ultrapure water and allowed 
to air-dry in a sterile environment.  Each substrate was then coated with a 
solution of 50 ng of VEGF in 50 µl of a mixture comprising 0.1% gelatin and 1% 
low-melting agarose in the ratio 1:1, and allowed to dry at room temperature 
overnight.  The substrates were then gently rinsed with PBS and allowed to dry.  
A second thin coating of the gelatine / agarose mixture was then layered over 
each substrate.  The substrates were rinsed with PBS and allowed to dry before 
use.  All the biological assays were done in duplicates, and each assay was done 




















 Plastic base 
PLGA suture mat 
VEGF-gelatin-agarose layer 
Gelatin-agarose layer 
Fig. 7.1  This schematic shows the cross-section of 
the suture substrate. 
Fig. 7.2  Photograph of the finished PLGA-VEGF 
suture substrate before being trimmed to size. 
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Assessment of the degradation rate of PLGA in solution 
 PLGA suture substrates were prepared as described above.  The 
degradation rate of PLGA in water, PBS and MEM-α supplemented with 10% 
FBS, was assessed by measuring the change in pH of the respective solutions.  
One piece of substrate each was placed in 10 ml of the respective solution, and 
the pH of each solution was measured on days 1, 5, 10, 15, 20 and 25. 
 
Stability of coated VEGF on suture substrates 
 For the assessment of the stability of VEGF on the suture substrates, the 
substrates were trimmed to size and placed individually in a 24-well plate 
containing 1 ml of PBS per well.  The amount of VEGF released from each 
substrate surface into solution was assessed on days 1, 5, 10, 15, 20 and 25.  At 
each respective point in time, 50 µl of PBS was removed from a well marked with 
the respective time-point.  The amount of VEGF in solution was then measured 
using the Bender Medsystems human VEGF ELISA kit, following the 
manufacturer’s instructions. The colour intensity of the reaction mixture was 
measured at 450 nm using an absorbance plate reader.  The amount of VEGF in 
the solution was determined using a series of VEGF solutions of known 
concentrations as standards which were prepared using a VEGF stock supplied 
in the ELISA kit.  The amount of VEGF at each point in time was then expressed 




 Human mesenchymal stem cells (hMSC) were seeded into cell culture 
flasks and cultured in a medium comprising Minimal Essential Medium-alpha 
(MEM-α), supplemented with 10% foetal bovine serum (FBS), L-glutamine 
(2mmol/l), penicillin (100 U/ml) and streptomycin sulphate (100  µg/ml), and 
incubated at 37oC in a humidified atmosphere of 5% CO2 and 95% air.  
Unattached cells were removed on the following day.  Half of the culture medium 
was replaced by a fresh aliquot of medium once every 2 days.  The attached 
cells were allowed to grow to about 75% confluence.  Cell colonies that were 
formed were identified and individually removed by gentle trypsinization, seeded 
into a new flask each and allowed to grow to about 75% confluence before being 
used.  Passage 2 hMSCs were used throughout the present study.  Attached 
cells were detached by trypsinization and resuspended in fresh culture medium 
for subsequent experiments described below.   
 
Flow cytometry 
 Cells were detached by trypsinization and then incubated in PBS with 2% 
FBS for 10 minutes in an ice bath.  1µl of the CD133-PE antibody was added to 
the cells, suspended in 100µl of PBS with 2% FBS, in separate tubes. After 
incubation for 10 minutes in an ice bath in the dark, the cells were washed, 
resuspended in 1 ml of PBS, and analysed using flow cytometry.  A total of 
10,000 events were collected for the analysis. 
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Preparation of culture medium containing VEGF 
For the preparation of VEGF-containing medium, the suture was stitched 
onto both sides of each plastic substrate and coated with VEGF.  In subsequent 
discussions, these substrates will be termed double-sided substrates.  Five 
pieces of double-sided substrates were placed into a small petri dish, such that 
the substrates were completely submerged in 3 ml of culture medium containing 
2% serum.   
 
Effect of VEGF release from suture substrate on MSC differentiation 
 hMSCs were seeded onto cover slips, each placed in a single well of a 6-
well plate at a density of 5 000 cells / cm2.  Unattached cells were removed the 
following day, and the cells were allowed to grow for another 2 days.  The cover 
slips were then removed from the 6-well plate and individually placed centrally in 
a petri dish containing 5 pieces of VEGF-coated double-sided substrates which 
were lined along the inner circumference of the dish.  The negative controls 
comprised a petri dish with cells in normal medium and another dish with cells 
grown in medium that had uncoated substrates immersed in it.  A dish without 
any substrate but containing culture medium supplemented with 10 ng / ml of 
VEGF and 2% serum served as the positive control.  The experiment was carried 
out for 14 days.  Half of the medium was removed and replaced with fresh 
medium every third day.   
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Immunofluorescent (IF) microscopy 
 Cells cultured on the cover slips were fixed in methanol at -20oC for 10 
min and then rinsed with PBS.  Following which, the cells were incubated with 
the relevant fluorochrome-conjugated antibody (1:300) for 1 h.  For von 
Willebrand Factor (vWF) staining and Tie2 staining, where unconjugated primary 
antibodies were used, the cells were rinsed in PBS and further stained with FITC-
conjugated goat anti-mouse secondary antibody (1:300) for 1 h.  The cells were 
then viewed using a fluorescent microscope (Olympus IX71), at a magnification 
of 100X (for VEGFR2) and 200X (for Tie2, vWF and CD31). 
 
In vitro capillary-like tube formation assay 
 The assay was performed using 50 µl of BD Matrigel in each well of a 96-
well dish at 4oC.  The matrigel was left at room temperature for 1 h to allow it to 
solidify before use.  Cells grown on the cover slips were detached with trypsin 
and the excess trypsin was removed by centrifugation.  The cells were 
resuspended in normal cell culture medium and 2 000 cells in 50 µl of medium 
was plated onto the Matrigel.  The cells were then incubated for 3 h and the 




Assessment of the degradation rate of PLGA in solution 
The degradation rate of PLGA sutures in water, PBS and cell culture 
medium was monitored by measuring changes in the pH of the respective 
solutions over 25 days (Fig. 7.3).  The pH values show a decrease of about 1.09 
(water), 1.56 (PBS) and 0.93 (MEM) after 25 days.  The buffering capacity of the 
cell culture medium has probably contributed to the smaller change in pH as 




































Fig. 7.3  The degradation rate of PLGA sutures in water, PBS and cell culture 
medium was monitored by changes in the pH of the respective solutions over 25 
days (n = 2).  Error bars represent the standard deviations.  The change in pH is 
the smallest in MEM, indicating that MEM probably has a higher buffering 






Stability of coated VEGF on suture substrates  
The substrates were coated with a high concentration of VEGF in a 
VEGF-gelatin-agarose mixture to ensure that the entire substrate surface was 
covered with the angiogenic factor.  A thin layer of gelatin-agarose mixture was 
layered over the substrate to protect the VEGF from being removed due to 
abrasion, and to facilitate an even rate of diffusion of VEGF into solution.  VEGF 
was progressively released into solution and its concentration reached a peak at 
day 15 (Fig. 7.4).  Subsequently by day 25, VEGF concentration began to 







































Fig. 7.4.  Concentration of VEGF in solution, expressed as percentage of the 
initial coating concentration of VEGF on the suture substrate (n = 2).  Error bars 
represent the standard deviations.  VEGF is progressively released and its 
concentration in solution reaches a peak at about day 15, which corresponds to 
approxiamately 2.6 ng / ml (MEM), 2 ng / ml (PBS) and 2 ng / ml (water) per 





 Passage 2 hMSCs were subjected to flow cytometry analysis to check for 
the presence of endothelial cell progenitors.  No detectable CD133+ cells were 
found. 
 
In vitro differentiation of hMSCs into endothelial cells 
The hMSCs express the endothelial cell markers, Flk-1 (VEGFR-2), Tie2 
and vWF after a 7-day culture in medium with VEGF released from the VEGF 
suture substrates (Fig. 7.5a – 7.5c).  After a 14-day differentiation, the 
differentiated cells also show a weak expression of CD31 (Fig. 7.5d).  The ability 
of the differentiated cells to form a capillary network on semi-solid medium was 
demonstrated in an in vitro angiogenesis assay using Matrigel (Fig. 7.6a).  A 
visual count revealed that about 90% of the cells exposed to VEGF form tube-like 
structures.  hMSCs in the negative controls did not form any capillary network 



























Fig. 7.5.  Immunofluorescent staining reveals that the hMSC-derived cells show 
expression of EC markers, VEGFR2 (Flk-1), Tie2 and vWF (Fig. 7.5a – 7.5c) 
after a 7-day differentiation.  The weak expression of the late EC marker, CD31, 
was detected after a further 7 days of differentiation (Fig. 7.5d). 
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Fig. 7.6.  Endothelial cells differentiated from hMSCs display a capillary network 
formation on Matrigel.  A visual count reveals that about 90% of the cells form the 
network (Fig. 7.6a).  Untreated hMSCs remain as isolated, single cells on the 








 PLGA is a synthetic biodegradable polymeric material which has been 
used as a material for sutures, and for the fabrication of scaffolds in tissue 
engineering to provide temporary support for cellular survival and tissue 
development.  It has a controllable degradation rate, possesses suitable 
mechanical strength, and is also an easy material to mould into different shapes 
[180, 181].  Its adjustable degradation rate also makes it suitable to be used as a 
controlled release delivery device.  Unfortunately, PLGA usually needs to be 
chemically modified so that other molecules may be covalently grafted onto its 
surface.  Chemical modification may consequently weaken the mechanical 
strength of PLGA [179, 182].  Similarly, most bioactive molecules which are 
intended to be grafted onto PLGA usually also need to be chemically modified 
[183, 184].  For example, VEGF can be oxidized using periodate oxidation for 
subsequent grafting onto dihydrazide modified PLGA [181].  However, chemical 
modification of a bioactive molecule may inactivate it or alter its effective 
biological function.  The oxidized forms of two human VEGF isoforms, VEGF165 
and VEGF121, have been reported to lose their ability to bind to the VEGF 
receptor, VEGFR-2 [180].  While cell-surface heparan-sulphate proteoglycans 
can restore the VEGFR-2 binding ability of oxidized VEGF165 by playing a 
chaperone-like role, the same process cannot restore the VEGFR-2 binding 
ability of oxidized VEGF121.  Thus, the reported decrease in activity of VEGF121 
could probably be due to oxidative damage.  Hence, a method to functionalize a 
biodegradable material without compromising its mechanical strength and 
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degradation properties would be an advantage.  Similarly, bioactive molecules 
should be attached to a matrix without any alteration to their chemical structure 
which may consequently compromise their biological activity.  In the present 
study, a simple and effective method of coating PLGA sutures with VEGF was 
used.  PLGA degrades by hydrolysis into its constituent lactic and glycolic acids 
[63].  As degradation proceeds, the presence of more acidic groups may thus 
autocatalyze the hydrolysis process.  For this reason, it can be expected that the 
release kinetics of any bioactive molecule, in this case, VEGF, will be affected.  
The degradation of the PLGA sutures was studied by monitoring the changes in 
the pH of each of the solutions in which the sutures were submerged.  The 
results show that the PLGA suture substrates underwent a gradual degradation 
process.  The degradation in cell culture medium had the smallest change in pH.  
This could be due to the greater buffering capacity of the culture medium.  The 
control of pH in vivo could be an important consideration if PLGA were to be 
used as a delivery device, as large pH changes may affect the degradation rate 
of PLGA.  The in vivo environment is dynamic: as PLGA degrades, blood flow 
and tissue fluid surrounding the implant site would probably remove the products 
of degradation, and thus prevent the accumulation of the acidic break-down 
products. This would reduce the rate of autocatalytic degradation of the PLGA 
implant, and consequently prevent a massive release of the attached VEGF.  In 
the present study, the degradation rate of PLGA was correlated with the release 
profile of VEGF from the PLGA substrate over a similar length of time.  VEGF is 
chosen because it plays a key role in vasculogenesis and angiogenesis.  Owing  
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to this important role, VEGF is often used in the in vitro differentiation of 
haematopoietic stem cells or endothelial progenitor cells into endothelial cells 
[185-187].  VEGF is known to have a short half-life in solution [188].  Hence, it is 
paramount that VEGF must be continually released at an optimal rate so that 
there are sufficient biologically active quantities of it in solution to mediate EC 
differentiation.  The results show that VEGF is progressively released from the 
substrate surface and reached a peak on day 15.  This indicates that our PLGA 
suture substrate is capable of the sustained release of amounts of biologically 
active VEGF.   
 The hMSCs have been characterized by flow cytometry and confirmed by 
the supplier to express MSC markers including CD105.  Using flow cytometry, a 
further check was done to ensure that there were no endothelial progenitors 
present among the hMSCs.  The presence of CD133+ cells was not detected.  
The aim of the present study is to test if the VEGF released from the suture 
substrates can induce the differentiation of the CD105+ hMSCs into ECs.  The 
results show that the hMSC-derived cells expressed VEGFR2 (Flk-1), Tie2 and 
vWF after 7 days of VEGF-mediated differentiation.  However, CD31, which has 
been implicated in various biological phenomena, including cell migration, 
angiogenesis, transendothelial migration and modulation of integrin-mediated cell 
adhesion, was not detected on the differentiated cells after a 7-day VEGF 
treatment.  This is consistent with similar observations reported by other 
researchers [189, 190].  After a further 7 days of differentiation, the weak 
expression of CD31 was detected, indicating that this marker is expressed late in 
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EC differentiation.  Based on this finding, an in vitro angiogenesis assay was 
carried out.  hMSC-derived cells differentiated for 14 days in medium with VEGF 
released from the suture substrates plated onto a Matrigel surface.  The 
formation of a capillary network was observed 3 h after cell plating.  A visual 
count showed that about 90% of the treated cells form the tube-like network.  
Similarly, about 90% of hMSCs cultured in normal medium supplemented with 10 
ng / ml (positive control) form a capillary network on Matrigel.  Undifferentiated 
hMSCs in medium without VEGF (negative control) remained as single cells on 
the Matrigel.  As the hMSCs had been ascertained to be non-CD133+, the 
possibility that the differentiated cells originated from a small population of 
endothelial progenitors can be excluded.  Thus, the results indicate that the 
method used in the present study to coat the PLGA substrate with VEGF can 
retain the biological activity of this growth factor, and progressively release it to 
mediate EC differentiation.   
Various other methods of immobilizing bioactive molecules onto 
substrates have been reported, with most of them requiring extensive 
modification to the substrate surface and to the bioactive molecules.  Despite the 
potential risks that chemical and genetic modifications pose to the performance 
of both the substrates and the bioactive molecules, there have been some 
encouraging results.  Basic fibroblast growth factor (bFGF) loaded within heparin 
conjugated PLGA microspheres has been shown to be released gradually in vivo 
to support angiogenesis [191].  Heparin is a highly sulphated glycosaminoglycan 
that has binding affinities to various growth factors. Heparin also helps to mitigate 
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the mitogenic activity of growth factors through the growth regulation of fibroblast 
and endothelial cells [192].  Thus, heparin is commonly used in the fabrication of 
matrices for the controlled release of growth factors [200, 201].  Others have 
combined condensed plasmid DNA encoding osteogenic growth factors and 
angiogenic growth factors, together with bone marrow stromal cells for loading 
into PLGA scaffolds.  These scaffolds have been used for the in vivo induction of 
bone tissue regeneration and blood vessel formation [193].  Although not as 
potentially risky as cellular transplantation of virus-mediated genetically modified 
cells, substrate-immobilized plasmid DNA may result in the continuous secretion 
of a high level of a growth factor.  Thus, plasmid DNA encoding an angiogenic 
factor like bFGF may accelerate the growth of pre-existing tumours or occult 
cancer, although bFGF is only weakly oncogenic [203-208].  Furthermore, 
continuous delivery of a relatively high concentration of bFGF can possibly 
worsen diabetic retinopathy [194].  A growth factor can also be anchored to a 
substrate using a cysteine tag [195].   However, this method involves the genetic 
modification of VEGF and its expression in Escherichia coli.  The modified VEGF 
carries a cysteine tag that allows it to be conjugated to fibronectin using a cross-
linking agent.  Although fusion tag conjugates may be an attractive alternative to 
immobilize bioactive molecules onto implantable substrates, it involves extensive 
genetic modification and relies on the use of micro-organisms to express the 
modified protein.   
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Conclusion    
 PLGA is a suitable biodegradable polymer to be used for tissue 
engineering applications.  Its tunable degradation rate enables it to be tailored to 
suit its application.  The ease of moulding PLGA into structures with suitable 
mechanical strength and its degradation into harmless products in the body make 
it a potentially excellent controlled release delivery device.  However, the 
extensive chemical modification of PLGA during the functionalization process 
could potentially compromise its mechanical strength as well as render the 
attached bioactive molecules non-functional.  In the present study, the method of 
anchoring VEGF on unmodified PLGA suture substrates can enable the gradual 
release of the angiogenic factor from the substrate into the solution, to induce the 
differentiation of hMSCs into ECs.   
Each additional step in a modification procedure can potentially 
compromise the performance of an implantable device, as well as increase the 
risk potential associated with its application.  It is therefore reasonable to be 
concerned that extensively modified implants and bioactive molecules can be 
potentially hazardous in vivo.  Thus, simple functionalization procedures should 
be as widely adopted as possible.  The method of immobilizing VEGF onto PLGA 
substrates reported here possesses the advantage of ease of fabrication and 
poses a relatively minimal risk in vivo.  Thus, this method can serve as a model 
for the attachment of other bioactive molecules onto various types of substrates, 
especially for the fabrication of controlled release devices. 
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Chapter 8   
Concluding chapter for this thesis    



















The continual search for advanced orthopaedic biomaterials    
 The conceptual evolution of orthopaedic biomaterials has taken place over 
three generations, from the first generation of bioinert materials, through the 
second generation of bioactive and resorbable materials, to the third generation 
materials that are engineered to stimulate specific cellular responses at the 
molecular level.  This continual biomaterial evolution has taken the process 
toward the development of materials capable of instructive and smart functions.  
The fundamental strategy of smart biomaterials design remains largely the same 
as in the late 1960s when Larry Hench designed biomaterials containing calcium 
and phosphate in proportions similar to bone mineral [3].  Currently, the strategy 
has taken on a new dimension - to design smart biomaterials that can direct 
biological entities to entirely regenerate tissues.  The aim is to create a synthetic 
tissue or organ that can function as the original natural counterpart.  This 
ambition has taken biomedical engineering research to the molecular, cellular 
and macroscopic levels in investigating biological mechanisms occurring in 
tissues and organs, and biomaterial interfaces.  Hence, the trend in biomaterials 
development is shifting towards creating biologically active systems that can 
interact with the biological environment.  Thus, from tissue engineering with 
biomaterials as scaffolds combined with autologous cells, the interest has shifted 
toward creating smart biomaterials by incorporating bioactive molecules or 
peptide sequences into delivery substrates [196, 197].  The controlled release of 
bioactive molecules into the local environment or the attached peptide 
sequences serve to instruct the behaviour of adhered cells.  The surface 
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chemistry of a substrate has also been shown to modulate cellular behaviour.  
This is illustrated by the example of a class of biphasic calcium phosphate 
ceramic which can induce osteogenesis at non-osseous sites in vivo, without the 
need for attached cells on the ceramic or the delivery of incorporated bioactive 
molecules [198].  Thus the surface chemistry of a biomaterial may be exploited to 
create a surface that interacts with the biological environment.  A biomaterial 
surface can be engineered to allow the selective adsorption of morphogenetic 
proteins that induce osteogenesis.   
  
The evolving strategies 
 The current strategy in tissue repair is to design biocompatible constructs 
that restores the damaged function and stimulate specific biological responses 
[3].  The idea of a biomaterial that mimics biological responses is an exciting one.  
Orthopaedic biomimetic materials have been developed for hard and soft tissue 
repair.  The relatively new field of tissue engineering combines a biomaterial with 
cells to create an artificial tissue to replace damaged or diseased tissue.  Tissue 
engineering is thus an interdisciplinary field that puts together engineering 
principles and methods and life sciences to develop biological substitutes that 
restore, maintain and improve the function of damaged tissues and organs [199].  
Progress in biomaterial design have progressed to the stage where attempts are 
made at fabricating materials that can instruct physico-chemical and biological 
processes at biomaterial interfaces [3].  Osteoinductive biomaterials are able to 
direct bone formation in vivo but the mechanism of osteoinduction still remains 
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unclear [3].  Despite this, important parameters like the pore size of 
osteoinductive materials have been identified [200].  Also important are other 
biomaterial parameters that influence the formation of hard and soft skeletal 
tissue.  These parameters need to be taken into consideration in the design of 
smart biomaterials.  Some biomaterials undergo spontaneous degradation, 
hence the degradation mechanism need to be understood, especially if bioactive 
molecules are incorporated into the design of these biomaterials.  Degradation 
affects the release kinetics of loaded drugs and growth factors, an important 
parameter that has been considered in chapter 7.  A degradable biomaterial with 
a well-tuned degradation rate can be effectively used to deliver drugs and 
bioactive molecules to a localized region of the healing bone.  The presence of 
proteins on the surface of a biomaterial can affect protein adsorption on the 
substrate surface and consequently influence cellular behaviour [201, 202].  The 
charge and concentration of adsorbed proteins can determine their coverage on 
the substrate surface [203].  The quantity and conformation of adsorbed serum 
proteins on biomaterial surfaces could influence ionic exchanges and 
consequently biological activity, and thus determine cellular activity [204, 205].  
Thus, ligands can be attached onto biomaterial surfaces to serve to attract cell 
types with the appropriate cell surface receptors.  Other than surface physico-
chemical properties, the topography of biomaterials is also another important 
parameter which can be manipulated to induce specific cellular functions [3]. 
Other ways to enable smart biomaterials include creating multi-component 3-
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dimensional scaffolds, as well as attachment of different bioactive molecules to a 
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Smart & instructive strategies 
Fig. 8.1.  The convergence of scientific disciplines and technologies 
enables smart and instructive strategies for tissue regeneration.  (Adapted 
from Barrère et. al. Materials Science and Engineering: R: Reports 59 
(2008), pp. 38-71.) 
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Potential revolutionary biomaterials 
 More revolutionary developments in biomaterials could involve the 
incorporation of nanotechnology with tissue engineering [206].  The creation of 
self-assembling peptides can be realized with an understanding of the three-
dimensional structures of existing biomolecues and the availability of automated 
chemical synthesis processes [207-211].  Smart peptides can respond to 
environmental cues and self-assemble into nanofilaments and nanoropes offer 
much promise [212, 213].  These revolutionary smart biomaterials can interact 
intelligently with cells and peptide sequences, which can potentially be applied to 
orthopaedic implant materials.     
 Smart biomaterials that can respond to the body environment are potential 
candidates for the fabrication of extra-cellular matrix (ECM).  Biologically, natural 
ECM confers mechanical strength to the cell and maintains its integrity.  ECM 
components are intimately involved in the transduction of cellular signals that 
control tissue-specfic gene expressions mediated by growth factors [197, 214, 
215].  ECM made of smart biomaterials that mimic natural ECM would add a new 
dimension in tissue engineering.  Such artificial ECM, unlike natural ones like 
decellularized ECM, can potentially be safely used in vivo without causing 
immunogenecity [206]. 
 
The convergence of scientific disciplines and technologies     
 The evolution of biomaterials has been made possible through the 
convergence of a multitude of scientific disciplines and technologies (Fig. 8.1) [3].  
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The amalgamation of knowledge from biology, physico-chemistry, computational 
sciences, medicine and engineering / biomedical engineering paves a promising 
direction in which he design of biomaterials currently moves.  In the design of 
bone implants, smart and instructive strategies is the way forward, towards the 
emergence of a generation of orthopaedic biomaterials that can direct self-
healing of bone defects.    
 
The contributions of this project 
 The work done in the present thesis has enabled a better appreciation of 
the capabilities of specifically functionalized biomaterials and their potential to be 
used for the fabrication of implants.  The cell-based assays have also enabled a 
better understanding of the molecular and cellular events that occur in the 
differentiating cells which are attached on the substrate surface.  The present 
work forms the basis for future work on bone cell differentiation on metallic 
substrates.  The work done on the PLGA-VEGF substrate is a proof of concept to 
illustrate the use of a resorbable biomaterial as a controlled release delivery 
device for orthopaedic applications.  It, too, forms the basis for future work on 
using PLGA or any other resorbable biomaterial as a carrier for bioactive 
molecules.  Together, the work in the present thesis paves the way for further 
highly detailed work to be performed, for the creation of smart implants for 
orthopaedic applications, which are able to instruct the self-healing of bone 
defects.   
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Limitations of this project    
 Despite the contributions of this project, there are undeniably limitations.  
Limited technical, financial and time resources necessarily restrict the techniques 
employed, and the biological work done.  While the techniques of depositing a 
BMP2 coat on the titanium substrate, including the improved method mentioned 
in chapter 5, result in a stably attached BMP2 layer under in vitro conditions, this 
may not be the case under surgical conditions.  The gelatin-agarose layer used 
to coat the VEGF adsorbed on the PLGA substrate surface can similarly be 
easily displaced under surgical conditions.  A protective coating over the VEGF 
adsorbed on the PLGA surface serves as a reservoir to evenly release the 
VEGF.  However, a more durable coating material needs to be used.  All the 
biological assays were carried out under in vitro conditions.  The response of the 
cells attached on the titanium substrates in vitro may not reflect the response of 
the cells in vivo in the presence of the cytokine milieu.  The same can be said of 
the response of the endothelial cells in the case of the PLGA-VEGF substrate. 
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Possible future work   
 The work in the present thesis has shown that the creation of smart 
biomaterials for directing the self-healing of bone is feasible.  However, the 
BMP2 coat on the titanium substrate need to be stably attached enough to 
withstand abrasive forces.  One possible way to enhance the stability of the 
BMP2 layer is to sand-blast the substrate surface.  Sand-blasting creates tiny 
indentations on the substrate surface where BMP2 molecules may be attached.  
The indentations serve to shield the BMP2 molecules from abrasions.  The 
gelatin-agarose gel coating on the PLGA-VEGF substrate can be replaced by a 
more durable and resorbable crosslinked polyacrylamide gel.  However, 
acrylamide must be handled with caution.  Polyacrylamide is not toxic but 
unpolymerized acrylamide could be present in the polymerized acrylamide.  
Thus, the polyacrylamide used should be of similar quality as those used to make 
soft contact lenses.  Understandably, the technology used to make 
polyacrylamide of contact lens quality may not be available in a biomedical 
research laboratory, and could be a potential limitation unless a commercial 
supply is available.  Possible future work can also be done to examine the 
osteogenic effects of the Ti-CS-BMP2(gluta) substrate and the angiogenic effects 
of the PLGA-VEGF substrate in vivo.  An investigation into the immunological 
responses induced by the implantation of these two substrates should also be 
done.  Immune responses have an integral role in the process of bone healing.  
Hence, a detailed study of the osteoimmunology of bone healing in vivo will yield 
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useful information for improving the functionalization process of the two types of 
substrates examined by the present author. 
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